nasal drug delivery device

专利摘要:
nasal drug delivery device a compound delivery device for delivering a plume derived from a propellant and a drug formulation. the drug formulation is an intranasal dosage form in the form of a powder, suspension, dispersion or liquid. the propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. the drug deposited within the olgatory region is distributed to the brain, avoiding the blood-brain barrier. hdirofluoralkane propellant from a pressurized container is channeled to a diffuser and drug-containing chamber where the intranasal dosage form is aerosolized. the aerosolized intranasal dosage form passes through a mouthpiece, thus distributing a plume to the olfactory region of a user's nasal cavity.
公开号:BR112013022249A2
申请号:R112013022249
申请日:2012-03-05
公开日:2020-04-28
发明作者:Brunelle Alan；Relethford Joel；D Hoekman John；Hite Michael；J Y Ho Rodney
申请人:Impel Neuropharma Inc；
IPC主号:

专利说明:

Invention Patent Descriptive Report for «NASAL DRUG DISTRIBUTION DEVICE ^w ,
REBWÊNCXA CROSSED WITH RELATED REQUESTS
This application t-e claims priority of OS € 1 / 449,008, deposited on March 3, 2011 _f US 81 / 451,935, deposited on March 11, 2011, US 81 / 484,025, deposited on May 9, 2011 and US 81 / 498,974, deposited on June 20, 2811, the total contents of which are hereby incorporated by reference in their entirety here.
DECLARATION DOUBLE JÉ3VERNO'S INTEREST
This invention was made with the support of the United States government under the US Army SBIR grant h'81XWH ~ 10-0-0238. The government may have certain rights in this application.
FUNDAMENTALS
The central nervous system (OS) includes the brain, the brain t-ronoa and the spinal cord. The CNS is isolated from the outside world by various membranes that both cushion and protect the brain, brain stem and spinal cord. For example, the membranes that form the blood-brain barrier (BBB) protect the brain from certain blood contents. The blood-brain barrier (BCSFB) protects other portions of the CNS from many chemicals and microbes.
Traditional methods for releasing compounds into the CNS are typically invasive. For example, a pump implanted in the skull, such as an intracerebroventricular pump, can deliver a variety of compounds to the brain. However, implanting this pump requires brain surgery, which can cause a variety of serious complications. Certain compounds, epidural analgesics, for example, can be injected directly through the protective membrane of the CNS <However, this injection is impractical for most compounds.
Intranasal administration has traditionally focused on the distribution of drug solutions, such as a mist for topical release to the nasal epithelium. Due to the fact that the nasal cavity bed is easily accessible, the .15 nasal administration of drug products focused on the release of drug products locally into the nasal cavity or directly into the blood flow.
Much of the current brain research is focused on improving the drug being released to the brain by several 20 'formulations. Traditional approaches to improving the absorption of compounds into the brain by improving the formulation include (1) mucoadhesive formulations; 2) penetration enhancers; 3) liposomes; 4} vasoconstrictors; and 5) nanoparticles. Examples of various compounds with improved formulations include various cytokines, for example, tumor necrosis factors, interleukins and interferons discussed in US Patent 6,991,785 and growth and differentiation factor-5 {GDF-s) 5 and related proteins discussed in Publication VS 20100074959 »
Targeting drugs to the central nervous system (CNS) is a challenging task. IM large number of drugs, including biotechnology products, are candidates for the treatment of CNS diseases, but drug release is a problem for targeting the brain <one limitation in the treatment of brain tumors is that less than 1% of the therapeutic agents administered systemically are able to cross the BBB. The transport of small molecules through the BBB is the exception and not the rule, and 98% of all small molecules do not cross the bbb (Pardride, NeuroRx. 2005 January; 2 (1): 12, 2005); approximately 100% of large molecule drugs or genes do not cross bbb (Pardrids, NeuroNx. δ 2005 January; 2 (1): 1-2. 2005), BBB allows small lipophilic molecules (with less than 500 Da) to bloodstream from entering the OB (Pardridge, Arch Neurol 2002; 59: 35-40), Many major therapeutic agents are prevented from reaching the brain for the treatment of CNS diseases, such as, among others, Parkinson's disease, Alsheimer disease, depression, stroke and epilepsy (Pardridge, NeuroRx. 200S January; 2 (l) t 3-14). Disorders, including autism, lysosomal storage disorders, fragile X syndrome, ataxia and blindness, are serious disorders where there is little efficient treatment. In many of these cases, the gene underlying the disease is known, but release via B.8S is the limiting problem in gene therapy or enzyme replacement therapy, and no drugs have been developed,
The drug release of therapeutic compounds, for example, proteins, faces several challenges because of its instability, high enzymatic metabolism, low gastrointestinal absorption, rapid renal elimination and potential immunogenicity.
is There is a need for devices that can deliver compounds to the upper nasal cavity for direct delivery from the nose to the brain. Certain existing nasal drug delivery devices do not adequately boost the drug in the device. The drug's inconsistent propulsion 20 due to the user's inconsistent performance is also far from ideal »In addition, the cloud generated by these existing devices is very large. In addition, some drug products do not mix readily and / or remain suspended with propellants in an MDI-type device. Certain existing nasal drug devices rely on circumferential velocity to propel drug products into the olfactory epithelium. Traditional circumferential devices result in a lower percentage of compound deposited on the olfactory epithelium. A circumferential component in the aerosol cloud tends to result in a larger spray cloud with a portion of aerosol particles directed to the sides of the nasal cavity in the
I The lower part of the nasal cavity.
Better mechanisms for delivering desired agents to the brain, brain stem, and / or spinal cord are needed.
SUMMARY
A device for releasing a compound to the nasal cavity region is described, including a container capable of containing a propellant, a diffuser in communication with the container, a compound chamber in communication with the diffuser and a mouthpiece in communication with the compound chamber, in which the device is able to deliver the compound to the olfactory region of the nasal cavity.
In one aspect, the device includes a container that is pressurized.
In another aspect, the propellant includes HFA _f nitrogen
GU ÇFC.
In another aspect, the device includes a compound chamber containing a drug or an imaging agent.
In another aspect. the drug is an oxime. 5 In other aspect, the diffuser it's a fry. FmFLT. other aspect, the agent from image ament o is FDG ORIn yet another aspect, the device includes a
propellant, where the propellant is a pressurized liquid ♦
In yet another aspect, the pressurized liquid is hfa.
another aspect, the pressurized liquid hfa is released from the container and comes into contact with the diffuser, through which the diffuser converts the pressurized liquid HFA to gaeoscu HFA
In another aspect, the diffuser converts a smaller part of the pressurized liquid HFA to gaseous HFA.
In another aspect, the diffuser converts most of the pressurized liquid HFA to gaseous HFA.
In yet another aspect, the device releases at least 62.6% of the compound to the olfactory region.
In yet another aspect, the device releases more than 64.2% of the compound to the ClfatÕria region »
In another aspect, the device releases at least
54.3% of the compound <olfactory region.
.Still in another aspect, the device includes a container where the container it's a syringe, s syrette or cylinder. Still in another aspect, the compound is not a agent of
imaging,
In another aspect, the compound is not FDG,
In one aspect, the drug is in the form of a liquid suspension, liquid dispersion, powder or aqueous solution <
In yet another aspect, the device still includes a target guide »
In yet another aspect, the target guide assists in positioning the mouthpiece of the device in the user's olfactory region.
In yet another aspect, the devices still include an insertion opening in communication with the compound chamberx
In yet another aspect, the device also includes an indicator provided to alert the user to the length or amount of insertion of a capsule into the user's nasal cavity.
On a. aspect, the diffuser is porous.
In another aspect, the diffuser is heterogeneously porous.
In another aspect, the diffuser is homogeneously porous. In another aspect, the diffuser is extended.
Still in. another aspect, the diffuser is a disk-shaped member, including conical members containing distal openings,
In another aspect, the container is a metered dose inhaler>
In another embodiment, a device for releasing a compound is described, including a container capable of containing a propellant, a diffuser in communication with the container, a compound chamber in communication with the diffuser and a nozzle in communication with the chamber compound, in which the device is capable of releasing the compound to the ear, skin, oral cavity or eyes.
In another embodiment, a method is described for delivering drug to the olfactory region of the nasal cavity, including providing a container capable of containing a propeXant, a diffuser in communication with the container, a compound chamber in communication with the diffuser and a nozzle in connection with the compound chamber, in which, when activated, the device is capable of releasing the compound to the olfactory region of the nasal cavity.
In one aspect, the method includes the release of a drug for the treatment of an infectious disease, cancer or immune disease.
In one aspect, the method includes triggering the device to release the propellant from the container, through which the diffuser diffuses the liquid propellant from the container to a gaseous propellant, the gaseous propellant comes into contact with the compound in the compound chamber and the compound and the gaseous propellant leaves the nozzle of the device.
In another aspect of the method, the diffuser converts a smaller part of the pressurized liquid HFA to gaseous HFA.
In another aspect of the method, the diffuser converts most of the pressurized liquid HFA to gaseous HFA,
In yet another aspect of the method, at least 64.2% of the compound is released to the olfactory region.
In yet another aspect of the method, more than 64.2% of the compound is released to the olfactory region.
In another aspect of the method, the compound is a drug or diagnostic agent.
In another aspect of the method, the compound is a drug.
In yet another aspect of the method, the diagnostic agent is an imaging agent.
In yet another aspect of the method, the drug is an oxime.
In yet another aspect of the method, the imaging agent is fluordeoxyglucose or fluortimidine.
In yet another aspect of the method, the compound is not fluordoxyglucose.
In yet another aspect of the method, the compound is not an imaging agent.
In yet another aspect of the method, the drug is in the form of a liquid suspension, a liquid dispersion, a powder, liposome or an aqueous solution and combinations thereof.
In yet another aspect of the method, the device includes one or more target guides.
In yet another aspect of the method, the target guide will access the positioning of the device's mouthpiece in the user's olfactory region.
In yet another aspect of the method, the device further includes an insertion opening in communication with the compound chamber.
In one aspect of the method, the device includes an indicator provided to alert the user to the depth of insertion of the device into the user's nasal cavity.
In another aspect of the method, the diffuser is porous.
In another aspect of the method, the diffuser is heterogeneous porous.
In another aspect of the method, · the diffuser is homogeneously porous. In one aspect of the method, the diffuser is extended.
In another aspect of the method - the diffuser is a disk-shaped member - including conical members containing distal openings.
In one aspect of the method # the container is a metered dose inhaler>
In another embodiment, an intranasal formulation of an oxime for use in the treatment of exposure to an organophosphate is described.
In yet another embodiment, a method is described for releasing an oxime through the blood-brain barrier to a subject in need of it - including administering to the subject a therapeutically efficient dose of an oxime # in which the dosage is released to the upper olfactory region of the nasal cavity .
In one aspect of the method # the therapeutically effective amount of an oxime administered to the user is within the range of about 0 # OQ1 mg / kg to about 100 mg / kg.
In another aspect of method # the therapeutically effective amount of an oxime administered to the user is within the range of about 0.01 mg / kg to about 10 mg / kg.
In yet another aspect of the method # the apeutically effective amount of an oxime administered to the user is within the range of about 0.1 mg / kg to about 1 mg / kg.
In yet another aspect, the method described for releasing an oxime is for treating exposure to organophosphate.
In another embodiment, a method for delivering an oxime intranasally to a user is described, including providing an oxime nasal dosage foment, propelling the nasal dosage form with a propellant, and releasing the nasal dosage form to the nasal cavity of the user. user, so that the oxime is überades. for the nasal cavity and, subsequently, for the central nervous system and / or the user's brain.
In one aspect, the released oxime includes 2-PAM, MMB4, HIS, TMB4 or. Hlo7 and combinations thereof.
In another aspect, the nasal dosage form of oxime is a powder, an aqueous solution, a suspension or a lipid containing product and combinations thereof.
In another aspect, the user was exposed to an organophosphate drug, including sarin, tabun, soman, Russian VX or diisopropylfluorfos.fact and combinations thereof.
In another aspect, most of the oxime in the nasal dosage form is deposited within the nasal cavity.
In another aspect, a nasal dosage form of a muscarinic receptor agonist or a muscarinic receptor antagonist is released intranasally.
In yet another aspect, a nasal dosage form of atropine or scopolamine or combinations thereof is provided intranasally.
In yet another aspect, a nasal dosage form of a benzodiazepine antagonist is provided intranasally »
In yet another aspect, the benzodiasepiuic antagonist includes diazepam, midazolam or lorazepam or combinations thereof.
In yet another aspect, the nasal dosage form is a benzodiazepine antagonist, a muscarinic receptor agonist, or a muscarinic receptor antagonist or combinations thereof <
In yet another aspect, the intranasal dosage form includes diazepam, midazolam, lorazepam, atropine or scopolamine or combinations thereof,
In yet another aspect, the nasal dosage form is released into the nasal cavity of the user exposed to an organophosphate.
In another aspect, the nasal dosage form is released into the user's nasal cavity before exposure to an organophosphate,
In yet another aspect, the nasal dosage form is released into the user's nasal cavity after exposure to
X4 an organofestate.
In yet another aspect, exposure A exima increases exposure to oxime for CNS <In other aspects, at least 53% of oxime is directly transported (DTP) to the brain.
The invention will be better understood using the following detailed description of various modalities, taken in conjunction with the accompanying drawings. The discussion below is descriptive, illustrative and exemplary and should not be taken to limit the scope defined by any of the attached claims.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic drawing of an embodiment of the invention
FIG.
shows an embodiment of the invention.
FIG.
shows an embodiment of the invention.
FIG shows another embodiment of the invention.
FIG.
shows another embodiment of the invention.
FIG.
shows another invention modality>
FIG shows another embodiment of the invention
FIG.
shows another embodiment of the invention with a fixed nasal guide,
FIG. 3 shows a modality of a diffuser and compound chamber, in which the diffuser is cylindrical and homogeneously porous.
Fig. 10 shows an embodiment of a diffuser and compound chamber, in which the diffuser is cylindrical and homogeneously porous with an open, non-porous pointed cone extending to the drug product.
FIG. 11 shows an embodiment of a diffuser and compound chamber, in which the diffuser is cylindrical with an open pointed cone extending to the drug product and is homogeneously porous.
FIG »12 shows an embodiment of a diffuser and compound chamber, in which the diffuser is cylindrical with many pointed open cones extending from it, which allows the gaseous propellant to enter the compound chamber,
FIG. 13 shows an embodiment of a diffuser and compound chamber, in which the diffuser is cylindrical with many cones extending from it, which allows the gaseous propellant to enter the drug chamber. It also includes a tube that allows the propellant to enter the compound chamber before the drug to aid aerosolization>
FIG <14 shows an embodiment of a diffuser and compound chamber, in which the diffuser is cylindrical and homogeneously porous. It also includes a tube that allows the propellant to enter the compound chamber before the drug to aid aerosolization.
FIG. This shows an embodiment of the invention, in which the proponent is created by manual air compression.
FIG. A shows an embodiment of the device that has a compound chamber within the body of the device 5 that allows the flow of propellant to flow through and around the compound chamber. FIG. 16 B shows a cross section of the device of FIG. 16 A.
FIG. 17 shows a schematic drawing of the device used to deliver 2-PAH drugs to mice in Example 1.
FIG, 18 demonstrates device deposition testing
POD in the nasal cavity of 2-PAM rat (dark shading) being deposited in the olfactory region (light circle). Few drugs were deposited in the respiratory region of the nasal cavity and none were found in the trachea or esophagus.
FXG. 19 is a graph showing the administration of
POD from a dose of 2.5 mg of 2-pam which resulted in significantly lower plasma values at all points in the first 60 minutes and plasma AUC globally plus 20. Lower. * ®p <0.05.
FIG. 20 is a graph demonstrating FOD administration of a 2.5 mg dose of 2-PAM which resulted in significantly higher brain values at 5 and 120 minutes and overall higher brain AÜC. * * p <0, $ 5.
FIG. 21 shows the model of the human nasal cavity, which was used in the deposition test of the model drug of flurescein described in Example 3.
FIG. 22 shows a processed image of deposition in the human nasal cavity, as described in Example 3, Five separate parts, vestibule, turbinates, olfactory base and esophagus were analyzed for deposition after spraying the device. FIG. 22 shows most of the spray being in the olfactory region.
.0 FIG, 23 is a schematic diagram showing the experimental configuration for the impact test described in Example 4>
FIG. 24 is a schematic of the experimental setup for estimating any temperature changes on a .5 surface that the device targets, which is described in Example E, W, laser thermometer was used to measure the temperature of the surface of a target. The device sprayed only KFA gas or HFA gas mixed with a dose of liquid and any temperature fluctuations were noted>
DETAILED DESCRIPTION OF THE MODELS
Unless otherwise defined, all technical and scientific terms used here have the same meaning as is commonly understood by experts in the art relevant to the described methods and compositions. As used here, the following terms and phrases have the meanings assigned to them unless otherwise specified:
As used here, the specification, W or one means one or more.
A diagnostic agent refers to and includes an atom, molecule or compound that is useful in diagnosing a disease. Diagnostic agents include, but are not limited to, radio, soot, dye, contrast agents, fluorescent compounds or molecules and potentializing agents (for example, paramagnetic ions). A non-radioactive diagnostic agent is a contrast agent suitable for the generation of magnetic resonance, computed tomography or ultrasound. the diagnostic agent can be used to perform positron emission tomography (TSE), hri, X-ray, tomography, ultrasound, operating procedure, intravascular, laparoscopic or endoscopic <
A diffuser refers to and includes a device for
disperse or deflect jm composed in multiple directions, One fry must refer to and incl Remove a filter or porous member. an agent gives imaging re fare if and includes a atom molecule or < compound that it's useful in detecting
physical changes or produces images of the internal tissues
1.9 of the body. In some ways, the imaging agent can be a diagnostic agent.
A * propellant ”must refer to and include a compound that acts as a vehicle for creating propulsion or impulse.
therapeutically effective amount ** refers to and includes an amount of a drug efficient to treat a disease or disorder in a mammal. In one aspect, the therapeutically effective amount refers to a concentration of the target ONS that has been shown to be efficient in, for example, slowing disease progression. The effectiveness can be measured in a conventional way, depending on the condition to be treated.
The terms treatment ** and treat **, and the like, refer to and include therapeutic or suppressive measures for a disease or disorder, leading to any clinically desirable or beneficial effect, including, without limitation, relief or alleviation of one or more symptoms , regression.
delay or interrupting progression gives disease or 2δ disorder. 0 treatment can be evidenced side as an decrease d the severity of a symptom, of number in
symptoms or frequency of recurrence.
IM user ** 'or subject * must refer to and include a human or other animal. For example, the animal can be a primate or a non-primate and can include a rabbit, bovine, equine, pig, rat, mouse, dog or cat,
The device can be used in the treatment, prevention, palliative care for human and veterinary purposes, the device can be used in research and industrial uses.
For example, the device can be used to deposit compost in agricultural environments.
When trade names are used here, the deponents independently intend to include the brand name product formulation, the generic drug and the active pharmaceutical ingredient (s) of the trade name product.
For clarity of disclosure and not as a limitation, the detailed description of the invention is divided into the following 15 subsections.
The intranasal administration of compounds offers several advantages over the traditional surgical, intravenous or oral routes for administration through the blood-brain barrier (BBB). Intranasal administration to the olfactory region avoids gastrointestinal destruction and first-pass hepatic metabolism, such as the destruction of drugs by liver enzymes, allowing more drugs to be cost-effective, fast and predictably bioavailable than if it were administered orally. Intranasal administration provides ease, convenience and safety »Intranasal drug administration is generally painless (taking into account that pain can be a subjective measurement that varies with the patient) and does not require sterile technique, intravenous catheters or other invasive devices and it is generally readily and readily available to all patients. Intranasal administration can quickly reach therapeutic drug concentrations in the brain and spinal cord »
Compounds administered via the nasal contact the upper olfactory region and molecular transport occurs directly through this tissue and in compartments of the central nervous system. (Henry, et al., Pediatr
Dent, 1998. 20 (5): p »321-6; âakane, T », et al», J Pharm
Pharmacol, 1991. 43 (6): p. 449-51; Banks, W.A., et al., J Pharmacol Exp Ther, 2004. 300 (2) j p. 469-75; Westin, et al., Pharm Hes, 2608. 23 (3): p. 565-72), The olfactory mucosa is located in the upper nasal cavity, then lower the cribriform plaque of the skull »This mucosa contains olfactory cells that cross the cribriform plaque and extend into the cranial cavity» When compounds come into contact with this mucosa specialized, they are quickly transported directly to the brain, bypass the BBB and are quickly transported directly to the central nervous system, often more quickly than if the compound were administered intravenously.
The olfactory mucosa includes the olfactory epithelium, the olfactory epithelium is located in the upper part of the nose between the upper turbinate and the roof of the nasal cavity, just below the cribriform plaque of the ethmoidax bone »In himnos, it covers about 1.0 to about 20 cm2 , or about 8% of the total nasal surface area and 1G is composed of four types of main cells; epithelial cells, olfactory receptor neurons, support cells and b & salts cells. (Mathison S. et al ,, (1998) Journal of drug Targeting 5; 415-441). Although 3% of the nasal cavity is occupied by an olfactory epithelium (Morrison and Costanzo, IS 1990), this pathway is direct, since olfactory neurons do not have a synapse between the receptive and
the afferent route (Ding and Dahl, 3003), 0 epithelium olfactoryhas more than two wzes a deep. age ;It's from epitheliumrespiratory, c < xn o s bodies c « 5 cell phones of nerve olfactory 20 normally located in regions cei straie and ma. is
deep in the epithelium, while supporting cell nuclei are organized in a single layer closest to the mucosal surface. Tight junctions exist between support cells and between support cells and olfactory nerve cells. Morrison E.E, et al. (1952} «Journal of Comparative Neurology 297 (X); 1-13 ..
When a nasal drug formulation is released deep and high enough in the nasal cavity, the olfactory mucosa is affected and drug transport to the brain and / or CSF via the olfactory receptor neurons occurs. The transfer of compounds from the nose to the brain is referred to as the nose-brain pathway. The nose-brain pathway has implications when drug products that act centrally, such as, among others, sedative drugs, anticonvulsions and opiates are released via the nasal route, the present device allows the release through the nose-brain pathway allowing the almost immediate release of nasal drug products for the central nervous system and the brain, bypassing the blood-brain barrier.
The current challenge in releasing the drug from the nose to the brain is also due to the complex architecture of the nose, which is naturally designed for channel dredgers in the lower nasal airway towards the lungs making it difficult for drugs to reach the olfactory region. Most of the drug dispensed from traditional nasal devices such as sprays or pumps is subject to the natural circulation of air in the nasal cavity towards the esophagus. Most of the spray dispensed from traditional devices finds the displacement of the natural downward air flow within the nasal cavity. The remaining fraction of traditional devices is found in the respiratory epithelium and eliminated by the mucociliary elimination mechanism or absorbed into the bloodstream.
While the instillation of nasal catheter and nasal drops are less impacted by this downward movement of natural air _f this requires subjects to be in a supine position, it is often associated with user discomfort and is not ideal for frequent clinical administration.
In addition, a reservoir of residual air exists at the top of the nasal cavity that is not removed during normal breathing; thus, remaining in the olfactory region and acting as a barrier to deposition. This residual air must be displaced to deliver aerosclized drugs to the olfactory epithelium in the upper nasal cavity in a consistent manner. The device described here releases most of the aerosolized drug to the upper part of the nasal cavity to increase the exposure of the drug in the olfactory epithelium, a site in the nose-brain pathway, preventing the downward movement of natural air and displacing residual air from the nasal cavity higher.
The device here, advantageously and consistently, deposits a large fraction of the dose in the most distal parts of the nasal cavity, such as the olfactory region. »A drug product (also referred to here as a drug formulation or nasal dosage form) is propelled from the device with a 5 speed in the nasal cavity <
Figure 1 shows an embodiment of the device where a container 10 contains a propellant. The propellant can be pressurized. Propellant G is a fluid, for example, a liquid or gas. In one aspect, the propellant is a liquid.
In another aspect, the propellant is a gas. Propellants include pharmaceutically appropriate propellants <Some examples of pharmaceutically suitable propellants include hydrofluoralkane (hfa), including, without limitation, HFA, HFA 227 _; HFA 134a, HFA-FP, HFA-BF and similar HFAs.
In one aspect, the propellant is a liquid HFA. In another aspect, the propellant is a gaseous HFA. Additional examples of suitable propellants include nitrogen or chlorofluorocarbons (CFC). In addition, propellants can be pressurized air (for example, ambient air). Container 10 can be a conventional metered dose inhaler (MUI) device that includes a pressurized container, calibration valve (including stem) to measure the propellant in action. In certain aspects, the propellant is not calibrated in performance. In one aspect, container 10 contains no drugs.
In another aspect, the container includes a propellant and a drug.
container 10 is in communication with a diffuser.
For example, when the diffuser is in communication with the lü container, communication * must refer to and include congruence or fluid communication. Propellant from container 10 is diffused through the diffuser. In one aspect, most of the propellant is diffused through the diffuser. In another aspect, the smallest part of the oropelente is' ** A X10 diffused through the diffuser. Most refer to and include at least 50 percent. The smallest part refers to and includes less than 50 percent. In another aspect, at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or about
100%, including the extreme points, of the propellant is diffused through the diffuser. The diffuser is in communication with the compost chamber 14 <The compostol chamber 4 is capable of maintaining a compound, such as, among others, a drug and / or a diagnostic agent. On a. aspect, the diagnostic agent is an imaging agent. In one example, the imaging agent is fluordoxyglucose (EDG) or fluortimidine (FX.T). In another aspect, the compound is a drug. In another aspect, the compound is not an imaging agent. In one aspect, the compound is a liquid. In another aspect, compost is a bread. In yet another aspect, the compound is an intranasal formulation of a drug in a liquid or powder state. The intranasal formulation may contain intranasal carriers and appropriate excipients known in the art.
The propellant in container 10 acts as a vehicle to release the propulsion or impulse to expel the compound from the compound chamber 14. The compound chamber 14 is in communication with a nozzle 16. The propulsion or thrust of the propellant 10 is capable of expelling the compound from the compound chamber 14 and nozzle 16 when in communication with the compound chamber 14 <
In one aspect, when the MDX device is activated, a discrete amount of pressurized HFA fluid is released. The CDM can contain between about 30 to about
300 performances, including extreme bridges, of HFA propellant.
The amount of propellant fluid released in the actuation can be between about 20 and about 200 pl, including extreme tips, of liquid propellant.
FIG. 2 shows a device modality. 0 body
actuator 20 houses a container 10, in one aspect O container 10 is a metered dose inhaler that includes one container propellant 18 strikes a neck 19 and one measuring valve assembly 21 <Orna valve stem 23
it is in communication with a connection channel 22. The propellant exiting valve stem 23 is a fluid. The fluid can be liquid, gas or a combination. The diffuser 28 is in communication with the props lens exiting the container 10 and the compound chamber 14.
Propellant exiting container 10 comes into contact with diffuser 28. Diffuser 28 is capable of converting liquid propellant exiting container 10 into gaseous propellant. In one aspect, the diffuser 28 is capable of converting all or most of the liquid propellant into gaseous propellant. In another aspect, the diffuser is capable of converting a minor part of the liquid propellant into gaseous propellant. Most refer to and include at least 50 percent.
The smallest part refers to and includes less than 50 per
15 cent. In other aspect, at least about 10%, 15%, 20%,25%, 30%., 35%, 40%, 45%, 5G%, 55%, 60%, 55%, 70%, 75%, 80%,S5%, 90%, 55%, 99% or about 100%, including the tales• X ·extremes, of propellant 1 .healthy liquid befits held in
gaseous propellants. After contact with the diffuser 28, the diffuse propellant comes into contact with the compound in the compound chamber 14. Q diffuse propellant and the compounds come into contact with each other as the propellant drives the compound in the compound chamber 114. The nozzle 18 is in fluid communication with the compound chamber 14. The compound is driven by the diffuse propellant in communication with the nozzle 15. the propellant impels the compound to be expelled through the distal end of the nozzle 15. exiting the nozzle 15 is the compound, propellant cu 5 a combination thereof.
In some respects, diffuser 28 serves to convert the propellant from a liquid to a gas. In other respects, the diffuser 28 serves to prevent the compound contained in the compound chamber 14 from coming into contact with the container 10 <Xô Another aspect, the diffuser acts as a one-way check valve, sm other aspects, diffuser 28 serves to convert the propellant from a liquid to a gas and prevent the compound contained in the compound chamber 14 from contacting the container 10. In yet another aspect, the diffuser serves to raise the temperature of the propellant.
An example of a diffuser 28 includes a frit, a plurality of fries, a diffuser member or combinations thereof. In one respect, the diffuser is a fry. In another aspect, the diffuser is a plurality of fries. In another aspect, the diffuser is a diffuser member.
In one aspect, the fries are of any suitable size and shape and are formed using any suitable porous material of any suitable density. In one aspect, the frit is prepared from a hydrophobic material. In one aspect, the frit is prepared from inert material to avoid chemically reacting with any of the compounds. The inert material can be metal or non-metal <In one aspect, the frit is composed of metal. In another aspect, the frit is composed of a non-metal. In one aspect, the inert material is sintered nickel. As an example, a frit formed using a porous stainless steel containing a pore size in the range of approximately 1 micron to approximately 10 microns can be used. In another aspect, the pore size is in the range of about 1 to about 10, about 10 to about 20, about 20 to about 30, about 30 to about 40, about 40 to about 50, about 50 to about 50, about 6 to about 70, 15 about 70 to about 80, about 80 to about 80, about 50 to about 100 microns, including the extreme points.
In another aspect, the fries can be formed using aluminum foam. The number and size of pores and the total dimensions (for example, diameter and thickness) of the frit are defined to maximize the surface area for vaporization while the limiting pressure drops following the passage of the vaporized propellant through the frit. In particular aspects, the fries can be made of Teflon, glass, metal mesh, canvas, porous metal, polyether ether or another plastic material »In one aspect, the passage of liquid propellant through the larger surface area of the frit» the transition from liquid to gas and increases the temperature of the resulting gas »
In another aspect, the passage of the gaseous propellant through the larger surface area of the frit increases the temperature of the gas.
As shown in FIG. 2, in one aspect, the diffuser is arranged in the connection channel 22.
In another aspect, the diffuser 28 is disposed within by which a diacostal shape in the drug chamber of an intranasal pharmaceutical drug chamber 24 is
24. A nozzle 25 is in communication with the drug chamber 24.
The diffuser 23, drug chamber 24 and nozzle 25 are housed in a drug capsule 30 adjacent to the driving body 20.
body of the drug capsule 30 may be of any material suitable for housing the components. In one aspect, the body of the drug capsule 30 can be constructed of plastic. In one aspect, the body of the drug capsule 30,0 may taper at the distal end to allow the mouthpiece 25 to be brought closer to the septum. The taper serves to improve the positioning of the device at an appropriate horizontal angle in relation to the upper nasal cavity.
Mgs trade · in FIG. 3 is another embodiment of the device. The actuator body 32 (or housing) houses the propellant container 34 containing a neck 33 and a metering valve assembly 35. (te valve stem 37 is arranged
S within a connection channel 35. The propellant exiting valve stem 37 is in a liquid form or in a mixture of liquid and gaseous form, a diffuser 44 is disposed in channel 36 and is adapted to convert most or all liquid propellant to gaseous propellant. Diffuser 10 44 is disposed within a drug chamber 42, through which the intranasal dosage form is disposed in drug chamber 42. A nozzle 48 is in communication with drug chamber 42. Diffuser 44, drug chamber 42 and nozzle 40 are arranged within a drug capsule 45 adjacent 18 to the driving body 32.
An insertion opening 38 is provided for inserting a compound into the drug chamber 42. The insertion opening 38 can be constructed from silicone or plastic. In one aspect, a syringe needle can be inserted through insertion opening 38 in order to inject the compound into the drug chamber 42. In one aspect, the compound is a drug. In another aspect, the compound is a diagnostic agent. In yet another aspect, the compound is not an imaging agent. The drug can be a liquid or powder.
Shown in FIG. 4 is another mode of the device.
A housing body 48 houses a pressurized propellant container 50, a connection channel 52, a release valve assembly 51, a diffuser 54, a drug chamber and a nozzle 58. The pressurized propellant container
5 $ contains a liquid propellant and has a release valve assembly 51. A connection channel 52 is congruent with the release valve assembly 51 of the container 50 and a diffuser 54 <the diffuser 54 is in communication with a drug chamber 56. In one aspect, the drug chamber contains an intranasal drug form containing drug, a nozzle 58 is in communication with the drug chamber 56>
Shown in FIG, 5 is another embodiment of the device.
A drive body 60 houses a propellant container 62 having a neck 61, a calibration valve assembly
S3 and valve stem 65, a valve stem 65 is disposed within a connection channel 72. The propellant exiting valve stem 65 is in a liquid, gaseous form or a mixture of liquid and gaseous forms. A diffuser 70 is arranged in channel 72 and is adapted to convert the liquid propellant into gaseous propellant. The diffuser 70 is in communication with a drug chamber 68.
In one aspect, the drug chamber 68 contains an intranasal dosage form. A nozzle 66 is in communication with the drug chamber 88. The diffuser 70, drug chamber 68 and nozzle 66 are arranged within a drug capsule 69 adjacent to the drive body 60. The drive body 60 is shaped allowing or accommodating a guide of target. The target guide includes one, a plurality or all of the target guides
nose 64, the septum target guide 74, a target target guide woolbio superior 76 a one visual indicator 71.In one respect, one nose target guide 64 is provided in the actuator body 60 . 0 naris target guide 5 64 serves to accommodate the nar. iz of user. In other- aspects to, the guide
nose target 64 serves to direct the mouthpiece 66 in the user's olfactory region.
In another aspect, a septum target guide 74 is provided in the drive body 68. In one aspect, the septum target guide 74 serves to accommodate the user's septum contact.
In another aspect, an upper wool target guide 76 is provided in the drive body 60
The upper wool target guide 76 serves to accommodate the user's upper lip contact.
In one aspect, a visual indicator 71 is provided to alert the user to the length or amount of insertion of the capsule 70 into the user's nasal cavity. In one aspect, visual indicator 71 is inserted up to a specific amount or length in the user’s nasal cavity,
Shown in FIG. 6 is another embodiment of the device.
a housing body SO houses a pressurized propellant container 94, a release valve assembly 91 and a connection channel 92. the pressurized propellant container 94 contains liquid propellant and has a release valve assembly 91. connection 92 is in communication with the release valve assembly and a diffuser 84. The diffuser 84 is in communication with the drug chamber 82. In one aspect, the drug chamber 82 contains an intranasal dosage. A nozzle 78 is in communication with the drug chamber §2.
In one aspect, a guide function is provided. The guide function includes a guide post 86. the guide post 86 is adjacent to a guide post arm 88. the guide post arm 88 is an integral part of a rotation arm 90. The rotation arm 98 can be attached or rotated attached to the housing body 80 in order to accommodate right- or left-handed users, guide post 86 guides the direction of the mouthpiece 78 into the user's nasal cavity entering the user's opposite nostrils and limiting the angle of administration. In one aspect, the guide post arm 88 and the rotation arm 90 are constructed of plastic. In yet another aspect, the guide post arm and the rotation arm are constructed of structural foam.
Shown in FIG. 7 is another embodiment of the device.
A housing body 98 is provided to assist with placement and to house the various component structures shown. A pressurized propellant container 108 contains propellant and has. a release valve assembly 107. A connection channel 104 is .10 disposed between the valve assembly, release 107 and a diffuser 102. Diffuser 102 is disposed within a drug chamber 100, through which the pharmaceutical form intranasal drug containing is disposed within chamber 100. A nozzle 96 is disposed in chamber 100.
Shown in FIG. 8 is a nasal guide 112, which can be added to the drug chamber 118> The guide would not obstruct the nozzle 116 or the orifices of the nozzle. 114 and would serve to limit the placement / insertion of the device into the nasal cavity to the desired administration angle.
FIG. 9 shows a modality of a diffuser 122 and its relation to the drug chamber 130> The propellant comes into contact with the diffuser 122. the diffuser 122 converts the liquid propellant into gaseous propellant. In one aspect, it converts most of the liquid propellant into a gaseous propellant. In another aspect, convert the smallest part of the liquid propellant into a gaseous propellant. In yet another aspect, it converts the entire liquid propellant into a gaseous propellant. In one aspect, diffuser 122 is cylindrical in shape. In yet another aspect, the diffuser 122 is congruent in shape with the compound chamber 130.
diffuser 122 is porous. The pores can be homogeneous in size and shape. In another aspect, the pores of diffuser 122 are heterogeneous in size and shape. In yet another aspect, diffuser 122 is homogeneously porous. In yet another aspect, the diffuser 122 is heterogeneously porous. As shown in FIG. 9, the diffuser 122 has a cylindrical shape and is homogeneously porous, so that the gas can pass through the pores, but the pores are impermeable to the drug product 124. The gaseous propellant then comes into contact with a drug product 124 driving the drug product 124 through a nozzle 128 and out of the device.
FIG. 10 shows another modality of diffuser 134 and its relationship to drug chamber 138. A propellant comes into contact with diffuser 134, propelling drug product 142 through a nozzle 146. A portion of the gaseous propellant exiting diffuser 134 is propelled through an extension of the diffuser 140, which assists in aerosolizing the drug product 142. As shown in FIG »15, diffuser 134 is heterogeneously porous through the extension of diffuser 140»
FIG. 11 shows another embodiment of diffuser 1.50 and its relationship to drug chamber 134, the propellant comes into contact with diffuser 150. diffuser 150 has an extended or elongated shape. In one aspect, the diffuser 150 has an extended cylindrical shape. The function of the extended cylindrical shape is to increase the area of the diffuser 150 in the drug chamber 154 and to contact any drug product
155 contained therein. A portion of the gaseous propellant contacts the drug product 155 by pushing the drug product 156 into a nozzle 160. Another portion of the gaseous propellant passes through the elongated or extended form, assisting in aerosolizing the drug product 156. As shown in FIG-11 , the diffuser 150 has a cylindrical shape and is homogeneously porous, so that the gas can pass through the pores, but the pores are impermeable to the drug product 155.
FIG. 12 shows another modality of the diffuser 164 and its relation to the drug chamber 166. The px * opelente contacts the diffuser 164. The diffuser 164 has a plurality of conical bridges, each with a distal orifice at the tip, so that the tips allow flow mainly of the gaseous propellant in the IBS drug product. the propellant comes into contact with the drug product 188 by propelling it through the nozzle 172.
Fig. 13 shows another modality of the diffuser and its relationship to the drug chamber 178. the propellant contacts the diffuser member 178. the diffuser member 17 $ has a plurality of conical points, each with a distal orifice at the end, so that the tips' allow flow mainly of the gaseous propellant in the drug product 10 180. A diffusion tube 182 allows the propellant mixture to bypass the drug product 180 into the empty space 184. The gaseous propellant exiting the diffuser member 176 comes into contact contact with the drug product 180 pushing it into the empty space 184 and through a nozzle 186.
1 ⁵ The diffusion tube 182 allows breathing to occur simultaneously with the use of the device. As a user uses the device, diffusion tube 182 allows inhalation by the user to avoid inhalation of drug product 180 contained in drug chamber 178. In addition, diffusion tube 182 allows the propellant to aerosolize the product of drug 180 as it contacts drug product 180 in drug chamber 178. Drug product 180 exits the aerosolized device. In another aspect, in the absence of diffusion tube 182, drug product 180 exits the nozzle with a liquid or partial aerosol or combination. In one aspect, a frit or a plurality of fries (not shown) is in communication with the diffusion tube 182 and / or diffusion member 178 in order to act as a check valve.
FIG. 14 shows another modality of diffuser 180 and its relationship to drug chamber 184. The propellant contacts diffuser 190 which is homogeneously porous, through which gans can pass through the pores, but the pores are impermeable to the drug product. A diffusion tube 196 allows the propellant mixture to bypass the drug product 192 in the empty space 197. The gaseous propellant exiting the diffuser 190 contacts the drug product 192 by propelling it into the empty space 197 and through a nozzle 198 .
The diffusion tube 196 allows breathing to occur simultaneously with the use of the device. As a user uses the device, the diffusion tube 196 allows inhalation by the user to avoid inhalation of the drug product 192 contained in the drug chamber 194. In addition, the diffusion tube 196 allows the propellant to aerosolize the drug product 192 as you contact the drug product
192 in the drug chamber 194. The drug product 192 exits the aerosolized device. In another aspect, in the absence of the diffusion tube 136, the drug product 192 exits the nozzle 198 as a liquid or partial aerosol or combination. In one aspect, a frit or a plurality of fries (not shown) is in communication with the diffusion tube 196 to 5 in order to act as a check valve.
FIG. 15 shows another modality of the device »The manual pressure trigger allows the user to administer the device without the need for a pre-loaded pressurized container or HFA container» This device has a piston 200 that is depressed in the compression chamber of air 202 resulting in an amount of compressed air maintained within the air compression chamber 202. Thus, the trapped air is increased from the ambient pressure to several times the ambient air pressure. In one aspect, the manual pressure trigger is a syringe or syringe. The device contains a locking pin 204 which is inserted to hold the piston in the high pressure position. In addition, the device contains a trigger valve 206. In one aspect »the trigger valve 206 is similar to a tap valve. There is a diffuser 208 in communication with the trigger valve 205 and the containment chamber 210. The compound is placed in the compound containment chamber 210, which is in communication with a nozzle 212. While the device is placed in the state of high pressure, the trigger valve 206 is placed in the loading position, which blocks the high pressure air in the air compression chamber 202, When the trigger valve 206 is moved to the open position by the user, the compressed air in the chamber air compression system 202 travels through the diffuser and into the compound containment chamber where it mixes with the compound. A mixture of compressed air and compound then exits the device through the nozzle 212, with a positive speed>
Fig. ISA shows another modality of the device that is suitable for releasing a compound into the nasal cavity of an animal or human. A pressurized propellant container 214 is in communication with a diffuser 216. The diffuser 216 is in communication with the interior of the .5 housing 21.8 and with the compound chamber 220. The interior of the housing 218 is in communication with a nozzle 222. A
FIG. 16B is a cross section of FIG. 16A on the dashed line. FIG. 16B shows that the compound chamber 220 is connected to the housing body 218 per flanges 224. The propellant is diffused by the diffuser 216 and the flanges 224 allow the diffuse propellant to travel through the compound chamber 220 and also around the compound chamber 220. When the pressurized propellant container 214 is activated to release a quantity of propellant, the propellant travels through the diffuser '216. ο dispersed diffuser ο propellant inside the shelter 218 and in the compost chamber 220 where the propellant mixes with ο compound, Ο propellant also travels outside the compound chamber 220 and then mixes with the compound leaving the compound chamber 220. Then the mixture of pharmaceutical compound and propellant comes out of the nozzle 222. As a user uses the device, the ratio of the chamber compound 220 to the housing 218 allows inhalation by the user to avoid inhalation of the drug product contained in the compound chamber 220.
The device can be for pediatric or adult use. A person skilled in the art can envision modifications of the device to accommodate for pediatric or adult use.
In another embodiment, the device releases a compound through the mucosa or epithelium of the tongue, mouth, skin or conjunctiva.
In another embodiment, the method includes administering a compound composition on or for the tongue, on or for the skin, on or for the subject's conjunctiva.
In yet another embodiment, the device releases the compound to the turbinate regions of the nasal cavity. In one aspect, the device primarily releases the compound to the turbinate regions of the nasal cavity.
Sm -Additional modalities, the device can be used for treatment, prevention or palliative care. The device can be used for research and industrial purposes. The device can be used to disperse a compound that has been driven by a propellant S, having been in communication with a diffuser. For example, the device can be used in agriculture to dispense an agricultural compound »
An intranasal formulation of an oxime Ó provided.
In addition, a method for intranasally administering an oxime 10 to the olfactory region is described »
Oximes can be released to the central nervous system (CNS) for the prevention, treatment, and palliative care of exposure to organophosphate compounds (OP), such as chemical warfare nerve agents (eg sarin, tabun, 15 soman, Russian vx, etc. .) or pesticides (for example, diisopropylfluorphosphate). Oximes are traditionally released, for example, intravenously. Intranasal administration of an oxime to. olfactory region allows transport through the BBB.
Nervous agents containing organophosphate compounds are a significant threat to the combatant, who can be exposed in battlefield scenarios on land, sea, air and space. Civilian populations also face health risks associated with nervous agents during the use of commercially available pesticides, as first responders for a terrorist attack. The current treatment regimen for nervous agent exposure includes the use of a cholinergic reactivator (pralidoxime, 2-PAM), muscarinic receptor antagonist (atropine) and an anticonvulsant (diazepam).
Although 2-PAM and atropine are available in multiple injection formats, (for example, XV infusion or XM autoinjector), the injection presents significant and practical challenges on the battlefield, such as the IG need to remove armor and have correct training in use of autoinjectors
In addition, more recent oximes such as MMB4 and HXÓ are difficult to formulate in current auto-injector formats. There is a great need to develop practical, more effective attack systems and 15 rapid capabilities to distribute nerve gas agents, such as oximes, capabilities to penetrate the central nervous system (cw) of subjects on the battlefield and emergency situations,
The method for releasing a specimen through the blood-brain barrier to a subject in need of it includes administering to the subject a therapeutically efficient dose of a specimen, where the dosage is released to the upper olfactory region of the nasal cavity.
In one aspect of the method, the therapeutically effective amount of a sample administered to the user is within the range of about 0.801 mg / kg to about 106 mg / kg.
In another aspect of the method, the therapeutically effective amount of an oxime administered to the
The user is within the range of about 0.01 mg / kg to about 10 mg / kg.
In yet another aspect of the method, the therapeutically effective amount of an oxime administered to the user is within the range of about 0.1 mg / kg to about 10 mg / kg. In one aspect, mg / kg is mg of compound per kilogram of body weight. In another aspect, the dosage is a fixed dosage regardless of weight.
In the performance of the method for delivering an oxime intranasally to the olfactory region includes providing the device 15 described here for insertion into the nasal cavity of the user.
The device is inserted into the user's nasal cavity. At least one therapeutically efficient dose of an oxime is delivered through the device. At least a theoretically efficient dose of an oxime is delivered to the clasp region. The release of the oxime to the olfactory region allows the release of the oxime through the 3BB.
Oximes such as 2-PAM (2-pyridine aldoxima methyl chloride), MMB4, HI6, TMB4, Hlo7 are currently used to treat OP exposure, but barely penetrate the blood-brain barrier. Thus, eximas, in their current form of administration, do little to treat or prevent CKS damage caused by these compounds.
Using the device described here for the method, the compound, such as oxime, can be self-administered, or administered by a battle or civilian colleague, or a user without prior medical training. The device releases compound without the need for a breathing pattern user-specific and can be managed on an unconscious user.
The percentage of direct transport (DTP%) to the brain was calculated using an oxime to determine the amount of drug in the brain that was delivered directly from the nasal cavity to the selves. In one modality, the 15 DTP was 62.6 +/- 9.8%. One aspect, DTP was greater than 64.2%. In another aspect, DTP was at least 64.3%. In another aspect, DTP was at least 53%. On the other hand, DTP was greater than 53%. In another aspect, the dtp was greater than 55%, In another aspect, the DTP was at least 20 about 55%, 60%, 65%, 70%, 75%, 80%, 85%, .90%, 95 %, 99% or 100%, including the extreme points. In another aspect, DTP was at least about 40%, 45%, healthy, 55%, 50%, 65%, 70%, 75%, 80%, 85%, 96%, 95%, 99% or 100%, including extreme points.
The device deposits a compound in the olfactory region. In one embodiment, the deposition percentage of the compost is at least 64.2%. In one aspect, the deposition percentage of the compound was greater than 64.2%.
In another aspect, the deposition percentage of the compound was at least 64.3%. In another aspect, the deposition percentage of the compound was greater than 50%. In another aspect, the percentage of deposition of the compound was greater than 55%. In another aspect, the deposition percentage of compound IO was at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100%, including the extreme points. In another aspect, the deposition percentage of the compound was at least about 48%, 45%, 505, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% , 99% or 100%, including the extreme 15 points.
The compounds that can be released by the described device include, among others, those for palliative, prevention or treatment of infectious diseases, inflammatory diseases and oncology. Compounds that can be released by the device include, but are not limited to, those for palliative, prevention or treatment of Parkinson's disease, Alzheimer's disease, depression, stroke, epilepsy, autism, lysosomal storage disorders, fragile X syndrome, ataxia , insulin deficiency and blindness. Compounds that can be released include, but are not limited to, # deferoxamine (DFO), glucagon-like peptide-1 antagonist, cephalexin, midazolam, morphine # insulin-like growth factor 1 # nerve growth factor 5, insulin, oximes # imaging agents, including # but not limited to .FOI »and FLT, GDF-3 and cytokines, including but not limited to interleukins (ie # II» -1, 2, XI »~ 3, IL4, xi» -5 # IL-6, xi »-8, XL-9 and XI» -10), interferons and tumor necrosis factor (ie # W- «and TNF-βί>
The invention is further described in the following examples # which are not intended to limit the scope of the invention,
EXAMPLES
Example 1 An oxime drug, 2-ΡΑΜ, was administered to the nasal olfactory region in rats with the device, (for example, a Pressurized Olfactory Release (POD) device).
The brain and plasma concentrations of 2-PAM were measured at certain points in time after drug administration. The release of 2-PAM made possible by device 20 resulted in greater brain exposure and less plasma exposure compared to intravenous injection,
Use of animals. The rats were used for deposition, tolerability and distribution experiments. Adult male prague-Dawley rats (200-300 g Harlan #
Indianapolis, XN) were housed under a 12-hour light / dark cycle with food and water provided ad libitum. The animals were treated in accordance with institutional standards, and all experiments were carried out using an approved Pacific Northwest Diabetes protocol.
Institute Institutional Animal Care and Use Committee under protocol number 12510,
Statistical analysis. In most cases where two values were compared, a t test was used. When 10 more than two groups were compared, such as comparing the powder formulation of 2-PAM POD with the aqueous formulation of 2PAM POD and 2-PAM IV, a two-way ANOVA with a bonferroni post-test was used . When comparing the plasma and brain ADC values that were derived from 15 different animals at each time point, the method described in
Westin et al., 2006 was used. In all cases, statistical significance was defined as p <0.05.
Aqueous formulations of 2-PAM were made by dissolving
2-PAM in deionized water. 2-PAM was dissolved in 500 pl of 20 mg / ml water, 100 mg / ml, 250 mg / ml and 500 mg / ml and left in a closed microcentrifuge tube at room temperature (25 * 09 <These formulations based on of water were then visually observed, in 1 hour, 24 hours and 48 hours for any turbidity or precipitation.
SI
2-PAM dry powder formulation was prepared by placing the free drug 2-PAM in a microcentrifuge tube and grinding the drug with a motorized pestle (Kontes, Vineland, NJ). The 2-PAM powder was then observed under a microscope to ensure homogeneity of the powder formulation. The 2-FAM was ground with a pestle to ensure that there was no agglomeration of 2-pam greater than 100 pm in diameter. These larger clusters could clog the 810 pm POD nozzle. in diameter used in experiments with mice.
The construction of the nasal POD aerosol device for mice is illustrated in Figure 17. A metered dose inhaler container (MDX) dispensing 25 µl of hydrofluoralkane 227 is attached to the plastic actuator. The driver is in gaseous communication with a polytetrafluoroethylene frit, which had a pore size of SO pm. The frit is in communication with the dose containment container that is placed inside the POU body, in order to create an aerosol flow. Upon performance, the HFA propellant is converted into a gas, passing through the frit material and then mixed with the dose and the dose and propellant mixture comes out of the 23 gauge stainless steel pipe nozzle, which is covered with a liner of the fluted ethylenepropylenc was placed on the outside of the metal tip to protect the nasal epithelium from being damaged by the mouthpiece during use. The construction of the mouse POD device was successful and consistently released powder formulations of 2-PAM with no measurable residual drug left in the device.
The basic operation of any POD device in mice was as follows. The animal was anesthetized with isoflurane S% for 2 minutes. To allow consistent administration, the rat was removed from the isoflurane chamber and placed in a supine position. The dose was loaded into the device and the mouthpiece was carefully placed at 0 mm center of the rat's nasal cavity and pointed towards the cribri formate plate. Then, the MDI container was pressed to discharge the dose into the rat's nasal cavity. In addition, the dry powder dose chamber was weighed on a scale with a sensitivity of 0.1 mg (Mettler Toledo, Columbus, oh) before loading the dose, after the dose was placed in the dose loading chamber and after burning, to ensure that the correct dose was loaded into the device and that the full dose was released into the rat's nasal cavity.
2-PAM formulations were prepared with 0.1% cocmassie blue tincture to test nasal cavity deposition in rats <Animals were treated using the dry powder POD device as described above, with a single dose of 2.5 mg of 2-PAM with coomassie blue. togo after the administration was complete (<5 minutes) the animals were applied with an excessive dose of 250 mg / kg of pentobarbital. The nasal cavity was then divided into the 5 septum, the septum was removed, and the tissues were examined for tincture location. In addition, the trachea and esophagus were dissected from the back of the mouth to the lungs to determine whether the POD spray deposited any 2-PAM beyond the nasal cavity »This 10 deposition study was conducted with N® 4 rats, the The normal result of the deposition tests is shown in Figure 18. In Figure 18, the olfactory region of the rat nasal cavity in the upper panel is circled in white. The dark dye can be seen to be deposited mainly within this olfactory region.
A sensitive MS method was established to determine the distribution of 2-PAM administered with POD in the plasma and brain of rats. A fixed volume (20 pi) of 2-chloro-1-methylpyridinium iodide (cerilliant, Paio 20 Alto, CA) was added to each tissue and plasma sample to act as an internal standard. Tissue samples were homogenized in 3 ml of water. 8 µl of acetonitrile was added to the samples to cause protein precipitation. The samples were centrifuged for 18 minutes at 10000g. Agilent IM HPLC / MS series 1100 series 8 with auto-trader (Agilent, Technologies, Inc., Santa Clara, CA) was used for quantification. The injection volume was 5 μ!> The morphine samples were passed over a Phenomenex Synergi 4u PolarRP BOA (Agilent, Technologies. <Xnc <, Santa Clara, CA) with a flow rate of 0.3 ml / min .
iThe standard curve was created on the day of analysis according to the same process described for the samples. Each standard curve was linear with a linear regression coefficient 0 R2> 0.99. In addition, two quality control samples with a known quantity of drugs were processed on the day of analysis to ensure consistency in the day-to-day of the analytical assay.
This LC / MS method was successful and resulted in reproducible quantification of tissue and brain samples. The detectable peaks of 2 ~ PAM were much higher than the bottom in most cases. The sensitivity of this detection method was 0.05 pg / ml in plasma and 1.0 ng in brain tissue. This method can be used in future studies with primates or in clinical studies.
In the tissue distribution experiments, the animals were anesthetized with 5% isoflurane for two minutes. Then, the animals were removed from the isoflurane induction box and placed in a supine position »The animals were then treated with the POD device (2.5 mg in a 1G μΐ Cmic dose) or by intravenous injection (2.5 mg in 500 pl} The animals that were sacrificed 5 minutes after dosing remained in anesthesia with 5% isoflurane until they were sacrificed.The animals sacrificed at the remaining time points were allowed to wake from anesthesia with isoflurane and placed in the shelter. minutes before sacrifice time, the animals were again exposed to 5% isoflurane, and then 0 were quickly administered with an overdose of Heuthanasia ~ D (Schering-Plow Animal Health Corp, North Chicago, XL). Using 2-PAM XV and the aqueous POD formulation of 2-PAM, the animals were sacrificed in 5 is, 30, 60 and 120 minutes (N ® 6}. Animals dosed with the formulation of 5 POD of 2-PAM seoo powder were sacrificed in 5 and 1S minutes®.
immediately after death, the animal was decapitated, blood was collected from the trunk and placed in a microaentrigug tube with 10 pl of 40 mM edta. the plasma was separated from the blood by centrifugation at é.GGOg for 10 minutes. Then the plasma was frozen until it was analyzed for the concentration of 2-FAM with the LC / MS method described previously. The base of the skull and the parietal bones were quickly removed from the head. The brain was removed within 2 minutes of sacrifice. The brain was placed in a microcentrifuge tube and frozen until it was analyzed for the concentration of 2-PAM with LC / MS.
a percentage of direct transport (DTP%) to the brain was calculated using an oxime to determine the amount of drug in the brain that was delivered directly from the nasal cavity to the ®. % Dtp is used to estimate the amount of drug in the brain that cannot be accounted for by systemic distribution. The DTP as defined was calculated as follows:
The administration of the aqueous formulation of 2-PAM with POD resulted in low systemic exposure and greater exposure of
CNS, compared to an equivalent IV dose. Dose IV resulted in a typical plasma curve with the highest point in 15 minutes (Figure 19). Q 2-PAM administered with POD resulted in plasma concentrations that were lower than XV values, which is not expected given the limited absorption of 2-PAM through the nasal respiratory epithelium into the bloodstream. The total plasma AUC was significantly lower after administration with POD compared to administration XV.
AO C cAAw wS <******** <^^
A 0 ^ jaBSMt (»<H« t) * “*., _<ΛΛβ .
OTF% ™ ____ _x 100 ^
Ad $ sosÇ
In contrast to plasma values, 2-PAM concentrations in the brain after administration with POD were significantly higher than after 5 IV administration in S and 120 minutes (Figure 20}. In addition, the total AUC concentration of brain was significantly higher after administration with POD compared to IV, of interest for the application of 2-PAM as a treatment for nervous gas exposure is the fact that in 5 10 minutes after administration, POD with 2-PAM resulted in 3.5
X concentration in the brain compared to IV administration.
The ratios between brain and plama were significantly higher after 2-PAM with POD compared to 15 IV at each time point, except in 30 minutes (Table 1).
These increased reasons point to the fact that a portion of the drug was released directly into the brain from the nasal cavity, effectively bypassing the blood-brain barrier. When the percentage of direct transport 20 (% DTP} was calculated, it was determined to be 80.3%. This% dtp can mainly be accounted for by the large values for the brain found 5 minutes after the administration of 2-PAM with PQD. 2 shows the ratios between concentration in the brain and the plama. At each point of time, except for 30 minutes, administration with POb resulted in significantly higher ratios between brain and plama with a ratio between brain and plasma increased by 15.25 times later 5 minutes.
Table 1
................................. iv ................ ............... ........................................... List * .......................... ...............................O.................. ............... ........................ ^r Ms * ..................... Ml ............................ ....Μΐ Oãí 4 * ”* .............. ............................... Ό .................. ............. w ...........................................................O................ .....
ίο The 2-PAM powder formulation administered via the POb device led to even higher 2-PAM concentrations in the brain (Table 2). The POD study with powdered 2-PAM was more limited than the aqueous formulation, but at 5 and 15 minutes after administration, powder formulation 15 resulted in similar levels in the blood compared to the aqueous POD with 2-PAM , but significantly higher concentrations in the brain.
Table 2
Table 2 shows the distribution of the formulation of 220
Powder PAM administered through POD. The pod powder formulation resulted in plasma values at 5 and 15 minutes that were not significantly different from the liquid POP formulation. However, concentrations of 2-PAM after 5 FQD administration of the powder formulation were significantly higher than ο aqueous 2-PAM with POP or ο 2-PAM via XV. * ®p <0.05.
The pharmacokinetic and distribution experiments resulted in data supporting the potential of 2-PAM Q administered with POD as a treatment for exposure to nerve gas. Administration with POD in the aqueous formulation and powder formulation resulted in high brain exposure within the first 5 minutes of administration.
Example <c device used in Bxempla 2 is described in Figure 3. The device in this example is referred to as a pressurized olfactory release device (POD). In order to determine the amount of compounds being released from the device to the olfactory region of the nasal cavity, a method was developed to determine the percentage of the dose deposited within the main regions of a human nasal cavity model. This method is based on quantification by image analysis and is able to detect and quantify deposition in 5 specified regions that describe the entire nasal model, including the upper olfactory region.
Materials: a model of the human nasal cavity was built from a moldable plastic lamination without heat. (Figure 21) This mold is thin-walled and transparent to a blue light source that allows the excitation of fluorescein from the indicator dye used in experimental doses. This model of human nasal cavity was based on a computer model generated from 10 multiple subject MRX exams (Liu, j Appl Physiol, 2009 Mar; 106 (3): 784-35). The model therefore represents an average human nasal cavity *.
Local XM to position the nasal models and target the POD device during targeting and the performance was designed and built. This location was flexible enough in operation to allow a wide range of horizontal and vertical steering angles. The direction of the device at different angles in relation to the nasal cavity, the robustness of the administration of the device could be tested.
The thin-walled transparent nasal model was prepared by coating the interior with a very thin layer of imitation mucus, which was simply a store-bought hand sanitizer solution. The prepared model was then photographed in a personalized photo / transilluminator box made as a blank reference for that particular experimental spot. The model was then assembled on site along with the ROD device 5 which was loaded with a dose of 0.1 mg / mL of
Pluorescein / water »As soon as the ROD was activated, the model was removed from the stage and kept horizontally to avoid dose migration. As soon as possible, the dosed model was placed in the photo / transilluminator box and 10 photographed. The model was then washed under a stream of tap water and dried by stirring or forced air to be prepared for another test. The images from the two cameras were then analyzed digitally as described below to reveal deposition within the model.
The processing of data from the blank and experimental images obtained was performed with the Imaged software.
For imaged to repeatedly compare images and perform subtraction of the background accurately, digital photographs were taken with the model carefully performed on the same record inside the photo / transilluminator box <imaged performs three main functions} 1) the image was processed in colors with the RGB channel splitter. This function eliminates red and blue signals from the image, leaving the main signal generated by the fluorescent signal of fluorescein in the dose.
The Imaged ROI manager allowed us to define five regions of interest; olfactory, turbinate, esophagus, base s vestibule, which were analyzed with each administration of the device. The regions are defined by the lines seen in Figure 20 and these regions contain a specific area, in pixels, that can be quantified based on the strength of the fluorescein signal. Figure 22 also shows a typical spray pattern after administration with POD. The fluorescein administered to the model by the POD device can be seen as the intensity of light on the dark background. It can be seen from Figure 20 that most of the administered dose resides within the olfactory region of the human nasal model, each pixel in these photos can have a value from 0 to 255. The Imaged measurement function calculates the average pixel value over each defined interest area. The total signal recorded within a given region of interest is, therefore, the product of the average pixel value by the number of pixels measured. For additional interest is the maximum value reported. Because the photo cannot record more than 256 signal levels, we can conclude that the test is not valid if we receive values of 255 in that column, because we are not sure that the actual signal is not significantly greater than 255, if can be measured, this situation would have the effect of underestimating the signal on that RGX because the signal is cut efficiently. For this reason, the camera's exposure settings are critical to ensure that the recorded signals were within the sensitivity range of the method even though they also allow maximum method sensitivity.
In addition, our calculations involved subtracting values obtained from a blank recording - this is 10 because there is some leakage of lost light and therefore, therefore, the potential for background fluorescence involving the model and the imitation of mucus. Due to the fact that these elements are not perfect in application, we can make a background photographic record each time and do a subtraction for each data point. This method offers the advantage of providing fractional deposition in more than one region of the nasal model. It also offers clear visual / qualitative photo confirmation of quantitative results.
The results of a deposition study are shown in Table 3. Two different POD devices were used and are referred to as tip # 1 and tip # 2 <Each tip was administered in the nasal model N ~ 3 times any horizontal angle of 0 degrees with respect to to the septum or 5 degrees horizontally towards the septum <All administrations with POD were administered at a vertical angle of 55 degrees in relation to the base of the nasal cavity.
Table 3
Tip # 10 degrees Tip # 1Previous 5 degrees Zone bistrib.Average Dev.Standard Distrib.Average Dev.Standard OÍfatôria 59.9 14.7 70.0 12.9 Turbocharged 38.3 13.2 35.1 5.3 Esophagus -1.4 4.7 -3.1 12.1 Basal 3.6 4.1 0.7 2.5 Vestibule -0.4 4.6 -2.7 2.8Tip # 2 Tip # 2G degrees Previous degrees Zone Dibstrib.Average Uesv »Standard Discrib.Average Uesv>Standard Olfactory 58.2 3.9 61.1 7.3 Turbocharged 0.1 12, í 38.5 3, 6 Esophagus -4.6 3.2 -0.1 4.6 Basal -0.8 1.5 -0.8 0.1 Vestibule -1.8 3.4 -0.4 2.3
Example 3
The impaction strength test was used to compare various nozzle / chamber configurations with MDI drivers for various commercial nasal spray products. Impaction force is an ideal method to characterize cloud characteristics that are important for consistency of dose release, location of dosing, dosing, comfort and safety. a schematic of the experimental setup used in this example is shown in FIG, 23,
Impaction force measurements were performed on a Mettler Toledo XS 64 with data output set to 10 per second, coupled with an Apple MacBook Pro 2.2 GHz Intel Cora 2 Duo processor, 4 GB 66 MHz DDR2 SDRAM via one ft. R8232 (Mettler Toledo) to USB cable (Gigaware) with 10 support driver software. Data acquisition was performed using Mindmill Logger version 4.07, version 7 (Windmill Logger Ltd.) in a Windows Vista virtual machine environment using Parallels Desktop 5 for Mac on the MacBook Pro. The data collected through Windmill Logger 15 was imported directly in Microsoft Excel for analysis and graphics processing.
An impaction force site was built to perform the measurements. This site included means for precise level and distance control together with custom brackets 20 for the individual devices tested. The actuation was performed manually. POD or commercial devices were aligned to impact the direct center of a 16.9 g and 74 x 80 mm aluminum pan. The pan was cleaned of dose / debris between each shot of data. The distance between the opening of the nozzle and the pan was 4 cm, consistent with the conclusions of Guo, et al. 2009 (Guo, J
Pharm Sei., 2009, Aug, * 98 (8): 27.99--905.) As being within the 3cm to emcm distance that generate the strongest impact and also consistent with our target distances in models human noses. ®I triggered values obtained by activating the valve, as tested, was largely insensitive from shot to shot, when used as directed. The only effects seen were lower values if triggered very slowly.
Three commercial nasal spray products have been tested
in this Example Rite Aid Pump Mist Muse 1 relief, oxymethololine HCX, v, £ '5 >; Me 11 Med NasoGei > For Dry Noses, Saline gel spray; and Rite Aid NoErip Nas al Spray, bomb,
oxymetazoline, 0.05%.
device used in this study is shown in
In Figure 3 and referred to as a pressurized olfactory release device (ROD) in this Example, the WD booal was compared to the commercial spray pumps tested above. In this example, we tested the POD device under the same parameters as commercial sprays using MEX containers loaded with 5% Ethanol, fluorescein mixed with HFA 134a or HFA 227. The Mbl valves were programmed to deliver a fixed volume of 50μ1.
Impaction forces measured by three commercial pump-style nasal sprays have been shown to generate floor forces generally below 0.8 grams. Bates products are noted for generating very wide spray patterns or slow-moving streams of gelatinous material. The forces generated from these tested products are in accordance with those cited by Guo et al ,, 2009, from 3.0 to 4.9 grams, the POD device generated impaction force measurements with peaks close to 4 grams, with a average just below d® 3 10 grams of strength when the most highly volatile 'HFA 134a was used. This force dropped to below 2 grams when HFA 227 was used instead. In both cases, the impact forces for the POD device are also in accordance with the impact forces measured for commercial MDX device 15 by Guo et al., 2089, which showed a maximum value of 6.5 grams,
It was found that the measured impaction forces are affected by the type of HFA used and the volume of HFA dispensed by the MDX container. The configuration of the 20-dose chamber and nozzle has an impact on the impact forces »In no case do we measure forces greater than that measured in relation to a commercial product referenced in the article by Guo et al.
Example 4
6S
In this example, the device, known as a pressurized olfactory release (POP) device, was tested to determine whether the device would release a cold temperature spray. This test involved measuring S surface temperature changes in the target region caused by HFA POD. The scheme of the experimental configuration used in this example is shown in FXG <24.
The hydroph. luoralkane (HFA) _f used as a propellant in the POP device is released from the 0 calibration vessel as a liquid. Very quickly after release, the HFA vaporizes and expands to form the pressure pulse that directs the dose through the POP nozzle. It is also a characteristic of POP with HFA that the HFA gas is expelled towards the white along with and after the 5 dose is released. The expansion of HFA causes a marked drop in the temperature of the propellant gas during the firing process. In order to establish whether this drop in temperature is transferred to the target tissues and to what extent, we design and perform experiments to detect: 0 and measure the surface temperature of the targets during and immediately after they are impacted by the device while releasing only HFA or when releasing a mixture of HFA and liquid compound (as it would be used to administer a liquid drug product).
6'9
Materials Kintrex infrared thermometer, model XRT6421, capable of measuring the surface temperature without actually coming into contact with the surface being tested. Temperatures are reported in degrees Fahrenheit.
A trigger equipped with a container of HFA 134a designed to release soul from the propellant, Kimwipe paper towels, Petri dish, IA ^- agarose / water, 3 tips, including a high impedance and low impedance nozzle and open configuration fries /absent.
Figure 24 illustrates the experimental setup for measuring temperature changes when triggering the POD device under different conditions. The thermometer was placed 4 cm from the target. At this distance, the thermometer ^{are seen, f} and reads from a circular spot diameter of 0.33 cm (ALVC circle in Figure 24),
Three leading edge configurations have been tested. 1. A tip with an adjusted high impedance nozzle. A high impedance nozzle is sufficiently restrictive for the flow of alpha gas that the nozzle is the limiting feature of the POD system. This releases the gas over a longer duration.
2. a tip with an adjusted low impedance nozzle. At this end, the frit, close to the end tip driver, is actually the limiting feature of the device. This releases the gas faster than the high impedance nozzle <3. A tip that does not contain a nozzle or fries. This tip essentially offers no restrictions for HFA gas or liquid flow through the device. ”With these three configurations, we hoped to understand how the 5 gas flow restrictions affect the target temperature after firing and also define the distinct function that the fry of teflon plays in diffusing and facilitating the transition of hfa from the liquid to the gaseous state.
We also tested the effect of the target's proximity to the nozzle with respect to temperature changes experienced by the target. We shoot at a distance of 4cm and 2cm.
In addition, we fire the device at three different targets »1) We use a very low mass target. This target was constructed from a Kimwipe paper towel. We 15 anticipated that a low mass target would have very low thermal inertia and, therefore, exhibit much more change in temperature after firing. 2) We created a simulated epithelium (mimicked epithelium # 1) by overlaying a Kímwipe paper towel on 1% agarose / mare. This was designed 20 for the thermometer to react to a color and texture surface similar to the low mass target. 3) Another simulated epithelium (mimicked epithelium # 2) made of 1% agarose / water with Kimwipe paper soaked just below the surface (less than 0.5 mm) of the agarose. This target was designed in case the thermometer reacted to the paper layer just below the essentially clear agarose to see if the temperature effects were mostly superficial.
In addition, some temperature measurements were made on the mimicked epithelium when a 50 μΐ dose of water was added to the configuration. Table 4 summarizes the temperature changes detected after firing only hydrofluoralkane propellant. The temperature change in degrees Fahrenheit is represented by the symbol
Δ. We believed and confirmed that this would create the conditions for the most dramatic temperature changes. With the low mass, target of low thermal inertia paper, the biggest temperature change was when no fries or booal was installed on the tip. The data for this condition has been narrowed together near In fact, with this configuration, particle or mist can be seen ejecting from the tip tip, suggesting that a certain fraction of the HFA remains liquid through its transit through the body of the driver and the tip.
Any liquid HFA that was supposed to reach the target would then be ablated on the target and could explain the dramatic temperature drops observed.
Table 4
Low impedance nozzleWithoutnozzle / friestarget at 4cmtarget at 2cm -Δ ~ & Hax-Δ -AMax-ΔLow mass 2.5 3.74.4 5.625.2 27.2 -í5jp.X X X oMímetíg &# 1 0.5 1.11.1 1.93.9 4.4 Epitheliummimicry # 2 1.0 1.50, 9 1.84.2 5.3High impedance nozzleWithoutnozzle / friestarget at 4cmtarget at 2cm -Δ -ΔΜοχ-Δ -2Max-Δ bMax Low mass 1, 9 3.22.9 5.225.2 27.2 Epitheliummimicry # 1 1.2 3.51.2 1.83.9 4.4 Epitheliummimicry # 2 1.7 2, 62.5 3.24.2 5, 3
In contrasts, all other experimental conditions resulted in much smaller temperature drops in the target.
Modest drops of 34 ° F were observed with the tip unobstructed in the mimicked epithelium. t It is clear that the thermal capacity of the target is critical in this analysis.
The inclusion of the nozzle and the Teflon frit at the tip resulted in even smaller temperature drops. Against the low tissue mass target, the low impedance nozzle
7 resulted in the largest drop in temperature, with a maximum value of s, 6 'F at a distance of 2 cm. The high impedance nozzle resulted in slightly lower temperature drops. Typical values were 3 * F or less.
There is a slight trend depending on the distance from the
tip to target. How would it be wait rar, shots in distance closer together may result in t standing: cataras more casualties in target. When a load of dose gives 50 pl of water was
added to the tip that included a Teflon frit and low impedance nozzle, very small temperature effects were observed. The data ranged between a drop of 0.5®F and an increase of 0.2®F. It was determined that, with views small change and dificuldade.de handle is liquid doses _f experimental setup we would not capaxes to obtain reliable data with liquid doses. However, we believe that the data collected with the liquid doses are consistent with the expected results.
The hydrofluoralkane propellant used in the POD device will have very minimal effects on the temperature of the impacted tissues. The data show the function of the Teflon fiber in the POD and the decrease in the temperature of the impacted site when only HFA is released. In addition, a typical SD uL load will likely reduce the temperature effects on its own.
Example 5
When analyzing the targeting of the human olfactory region with a drug product, 2 formulations of 2-PAM were released from the device in a human model of the nasal cavity and analyzed for olfactory deposition.
A model of human silicone nasal cavity was purchased from Koken Xnc. (Tokyo, dapão). a small amount (0.1%) of coomassie blue (SigmaAldrich, St. Louis, MO) was mixed with the dry powder of 2-FAM. The 2-PAM dry powder and coomassie blue were crushed to a homogeneous powder with a mortar and pestle. 0.1% of Rhodamim B was added to the aqueous formulation (250 mg / ml) for visualization of the nasal cavity model. The dry powder formulation was sprayed into the model nasal cavity (N ~ 10) with the device, and the photos were taken to obtain a qualitative measure of deposition in the olfactory region. The photos were judged as if most of the 2-PAM powder was deposited in the olfactory region.
the same was done with the aqueous formulation, and the deposition in the olfactory region was also quantified by weight for this formulation (N ® 10). The olfactory region of the nasal cavity model was cut from the model so that it was removable. The olfactory region was weighed before the POD spray and after the spray, and the percentage of the dose administered to the olfactory region was calculated by weight.
The dry powder formulation of 2-PAM administered in the human nasal cavity was efficient in depositing drugs in the olfactory region. The qualitative analysis of 10 administration attempts in the model was consistently considered to show the majority of the drug (about 50 % or more) in the olfactory region, In addition to the drug deposit 10 in the olfactory region, the dry powder device deposited a substantial amount of the dose of 2-PAM at the interface with the cribriform © plate of the model that separates the olfactory region from the cavity nasal brain.
The aqueous formulation of 2-PAM showed similar deposition patterns in the human nasal cavity model to the dry powder formulation. In addition to qualitative photos of the human nasal cavity, 62.5 ± 9.5% of the dose was determined to be deposited in the olfactory region of the nasal cavity.
The present invention should not be limited in scope by the specific modalities described here. In fact, several modifications of the invention, in addition to those described here, will be apparent to those skilled in the art from the foregoing description and the accompanying figures. These modifications are intended to fall within the scope of the added claims.

权利要求:
Claims (1)
[1]
CLAIMS characterized by pole âí characterized by characterized by syrette pole, on cylinder.
sitlvo, according to the claim characterized by the fact that it still comprises in or more earcharged by the fact that claims 1 or 6, characterized by the fact that the diffuser is porous.
10 <Device »· according to claim 8, characterized by the fact that the diffuser is heterogeneously
11. Device according to claim 8, characterized by the fact that the diffuser is horsocenously x>. ». K · · *. ·. V **. ·. ' S * 'vi -x- tx ^ x- v- «x« x- x .. · ·, ·. · “·. · · · · Xs« ν. ·· . · · * · * S ·· ·. · “**. · ··· user, characterized by the fact that he understands:
a compost chamber in communication with the diffuser, a compost chamber to contain the compound, and device is a distributor cap for an ear, skin, oral cavity, turbid area of the nose or eyes of the user.
13. Device according to any one of claims. 1 to 12, characterized by the fact that the compound is an exima.
14. Method for mtranasa.1 distribution of an ozone compound to an oral region of an expensive nasal cavmaae due to the fact that it comprises:
providing a device including a container capable of containing a propellant, a diffuser in communication with the container, a compound chamber in communication with the u.user, the compound chamber capable of containing the compound, and an injector in communication with the chamber of compound, in pue, when activated, the device distributes the compound to the olfactory region of the user's nasal cavity.
15. Use of a kidney-compliant device in any of claims 1 to m, characterized by the fact that it is for the intranasal administration of a compound to an olfactory region of a nasa cavicaae.
16. Method to distribute an exima across the blood-brain barrier to an individual in need of »iau« of the same characterized by the fact that it comprises:
administering to the individual a therapeutically effective quantmade of an oxime, in which the oxime is distributed to an olfactory region of a nasal cavity <
17, Use of ama oxíma characterized by the fact that ssr in the preparation of an infranasal formulation of tratasnio, prevention or palliative treatment of poisoning by exposure to organophosphide.
18, Use, according to claim 17, characterized in that an efficient therapeutic dose of exima is distributed to the olfactory region through uaviaaoa in a a. -
19, Use of an exima compound characterized by the fact that it is for the preparation of a device to distribute ozi.oa from the nasal cavity to the hi-iva region for treatment, prevention or palxative care for one. individual exposed to organophosphate,

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112013022249A2|2020-04-28|nasal drug delivery device

---

US11191910B2|2021-12-07|Medical unit dose container

---

Fletcher et al.2009|Intranasal delivery of erythropoietin plus insulin-like growth factor–I for acute neuroprotection in stroke

---

EP1258264B1|2007-12-26|Aerosol delivery apparatus

---

Charlton et al.2007|Distribution and clearance of bioadhesive formulations from the olfactory region in man: Effect of polymer type and nasal delivery device

---

PT2442821T|2017-09-29|Safe desmopressin administration

---

BRPI0610352A2|2010-06-15|oral drug delivery system and methods of using it

---

Kwatra et al.2012|Alternative routes of drug administration-transdermal, pulmonary & parenteral

---

Xu et al.2020|Design and application in delivery system of intranasal antidepressants

---

Cossío et al.2018|Preclinical evaluation of aerosol administration systems using positron emission tomography

---

Suman2003|Nasal drug delivery

---

Pardeshi et al.2015|Novel nasal devices for the efficient drug delivery: a systemic review

---

Stenslik et al.2018|Methodology and effects of repeated intranasal delivery of DNSP-11 in awake Rhesus macaques

---

Yenet et al.2010|Newer advancement in nasal drug delivery system

---

Reddy et al.2015|Principles of Drug Release In Various Dosage Forms

---

Bitter2011|Transmucosal nasal drug delivery: pharmacokinetics and pharmacodynamics of nasally applied esketamine

---

Nag2018|14 Drug Delivery Systems

同族专利:

---

公开号 | 公开日

---

AU2012223160A1|2013-09-12|

---

EP2680913B1|2020-05-06|

---

EP3679971A1|2020-07-15|

---

CA2828884C|2021-04-27|

---

AU2016256665A1|2016-11-24|

---

US10507295B2|2019-12-17|

---

US20200078544A1|2020-03-12|

---

CN103917265B|2017-02-15|

---

EP2680913A2|2014-01-08|

---

JP2014530637A|2014-11-20|

---

AU2016256665B9|2018-11-22|

---

CA3111516A1|2012-09-07|

---

JP6339371B2|2018-06-06|

---

AU2018256518A1|2018-11-22|

---

EP2680913A4|2015-08-05|

---

WO2012119153A3|2014-04-17|

---

US9550036B2|2017-01-24|

---

AU2012223160B2|2016-08-18|

---

CN103917265A|2014-07-09|

---

US20140014104A1|2014-01-16|

---

US20170043109A1|2017-02-16|

---

RU2728583C2|2020-07-30|

---

AU2012223160A2|2013-12-05|

---

RU2017105845A3|2020-05-25|

---

RU2612506C2|2017-03-09|

---

RU2013144395A|2015-04-10|

---

CA2828884A1|2012-09-07|

---

RU2017105845A|2019-01-21|

---

AU2016256665B2|2018-11-08|

---

WO2012119153A2|2012-09-07|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

GB806284A|1955-11-14|1958-12-23|Chi Ah Lai|A new or improved nasal inhaler|

---

US3425414A|1965-05-28|1969-02-04|William J La Roche|Inhalant dispenser|

---

US3888253A|1972-08-04|1975-06-10|Beecham Group Ltd|Device for administration of medicines|

---

FR2224175B1|1973-04-04|1978-04-14|Isf Spa|

---

GB1479283A|1973-07-23|1977-07-13|Bespak Industries Ltd|Inhaler for powdered medicament|

---

US3971377A|1974-06-10|1976-07-27|Alza Corporation|Medicament dispensing process for inhalation therapy|

---

US3908654A|1974-08-02|1975-09-30|Rit Rech Ind Therapeut|Dispensing package for a dry biological and a liquid diluent|

---

YU41046B|1974-08-22|1986-10-31|Schering Ag|Medicine inholating device|

---

US3998226A|1975-09-22|1976-12-21|Edward G. Gomez|Inhalation device for encapsulated concentrates|

---

ZA758010B|1975-11-14|1977-08-31|Syntex Inc|Nasal spray adapter|

---

SE408265B|1975-12-12|1979-06-05|Draco Ab|DEVICE FOR CARBON DIOXIDE POWERED ENDOSAEROSOL, INTENDED FOR INHALATION|

---

US4095596A|1976-11-26|1978-06-20|Smithkline Corporation|Nasal inhaler|

---

US4227522A|1978-09-05|1980-10-14|Syntex Puerto Rico, Inc.|Inhalation device|

---

US4187985A|1978-12-08|1980-02-12|The Continental Group, Inc.|Aerosol valve for barrier type packages|

---

IT1116047B|1979-04-27|1986-02-10|Sigma Tau Ind Farmaceuti|DEVICE FOR THE QUICK INHALATION OF POWDER DRUGS BY PERSONS SUFFERING FROM ASTHMA|

---

BR8007911A|1979-12-06|1981-06-16|Glaxo Group Ltd|PERFECTED INHALER|

---

EP0162854A1|1983-11-28|1985-12-04|Vortran Corporation|Gas-powered nebulizer|

---

US4702415A|1983-11-28|1987-10-27|Vortran Corporation|Aerosol producing device|

---

US4412573B1|1981-12-28|1985-10-22|

---

US4446990A|1982-04-03|1984-05-08|David J. Stevenson|Self-defense spray device|

---

WO1986001731A1|1984-09-18|1986-03-27|Vortran Corporation|All purpose nebulizer|

---

US4896832A|1987-09-07|1990-01-30|Bespak Plc|Dispensing apparatus for metered quantities of pressurised fluid|

---

IT1228459B|1989-02-23|1991-06-19|Phidea S R L|INHALER WITH REGULAR AND COMPLETE EMPTYING OF THE CAPSULE.|

---

US5624898A|1989-12-05|1997-04-29|Ramsey Foundation|Method for administering neurologic agents to the brain|

---

SG45171A1|1990-03-21|1998-01-16|Boehringer Ingelheim Int|Atomising devices and methods|

---

NZ238489A|1990-06-14|1995-09-26|Rhone Poulenc Rorer Ltd|Inhaler with capsule in swirling chamber: capsule pierced in chamber|

---

DE4038049C2|1990-11-29|1994-12-01|Anschuetz & Co Gmbh|Implantable infusion pump|

---

US5331954A|1990-12-21|1994-07-26|Novo Nordisk A/S|Device for nasal delivery of liquid medications|

---

IT1249600B|1991-02-21|1995-03-09|Elettro Plastica Spa|NASAL DISPENSER OF SPRAYED PHARMACEUTICAL SUBSTANCES|

---

US6681767B1|1991-07-02|2004-01-27|Nektar Therapeutics|Method and device for delivering aerosolized medicaments|

---

IT1250691B|1991-07-22|1995-04-21|Giancarlo Santus|THERAPEUTIC COMPOSITIONS FOR INTRANASAL ADMINISTRATION INCLUDING KETOROLAC.|

---

GB9125699D0|1991-12-03|1992-01-29|Glaxo Group Ltd|Device|

---

DE4239402A1|1992-11-24|1994-05-26|Bayer Ag|Multiple dosage powder inhaler - has acceleration channel and dwell chamber for uniformly high drug dispersion|

---

US5899201A|1993-05-26|1999-05-04|Minnesota Mining And Manufacturing Company|Aerosol actuator|

---

US5819730A|1993-06-09|1998-10-13|Glaxo Wellcome Australia Ltd.|Device for administering pharmaceutical substances|

---

US5349947A|1993-07-15|1994-09-27|Newhouse Michael T|Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow|

---

US5516006A|1993-07-30|1996-05-14|Meshberg; Philip|Nasal dispenser|

---

US5398850A|1993-08-06|1995-03-21|River Medical, Inc.|Gas delivery apparatus for infusion|

---

IT1266794B1|1993-11-09|1997-01-21|Faustino Ballini|MICRONIZED SHOWER DEVICE FOR WASHING THE NASAL AND NEIGHBORING CAVITIES|

---

DE4342174C1|1993-12-10|1995-05-11|Lohmann Therapie Syst Lts|Transdermal therapeutic system and a method for producing a transdermal therapeutic system for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of poisoning by highly toxic organophosphorus neurotoxins, in particular Soman and its use|

---

EP0759744B1|1994-05-13|2001-10-17|Aradigm Corporation|Narcotic containing aerosol formulation|

---

US5435282A|1994-05-19|1995-07-25|Habley Medical Technology Corporation|Nebulizer|

---

JP3372105B2|1994-05-26|2003-01-27|株式会社日立ユニシアオートモティブ|Inhalation type dispenser|

---

US5785049A|1994-09-21|1998-07-28|Inhale Therapeutic Systems|Method and apparatus for dispersion of dry powder medicaments|

---

US5901703A|1995-02-06|1999-05-11|Unisia Jecs Corporation|Medicine administering device for nasal cavities|

---

DE19518580A1|1995-05-20|1996-11-21|Thomas Ossinger|Electrically heated dip soldering crucible|

---

JPH08322934A|1995-05-29|1996-12-10|Unisia Jecs Corp|Dosing device for nasal cavity|

---

US7335186B2|1998-03-13|2008-02-26|Alexander George Brian O'Neil|Patient controlled drug delivery device|

---

DE19523516C1|1995-06-30|1996-10-31|Asta Medica Ag|Inhaler for administering medication from blister packs|

---

US5823183A|1995-08-02|1998-10-20|Innovative Devices|Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament|

---

GB9516984D0|1995-08-18|1995-10-18|Pharmasol Ltd|Spray applicator|

---

IE77523B1|1995-09-11|1997-12-17|Elan Med Tech|Medicament delivery device|

---

US5711488A|1995-10-13|1998-01-27|The Procter & Gamble Company|High pressure swirl atomizer|

---

US7033598B2|1996-11-19|2006-04-25|Intrabrain International N.V.|Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal|

---

US6410046B1|1996-11-19|2002-06-25|Intrabrain International Nv|Administering pharmaceuticals to the mammalian central nervous system|

---

US6678553B2|1995-11-21|2004-01-13|Intraabrain International Nv|Device for enhanced delivery of biologically active substances and compounds in an organism|

---

US5797390A|1996-03-06|1998-08-25|Mcsoley; Thomas E.|Nasal inhaler having a directed spray pattern|

---

US5875776A|1996-04-09|1999-03-02|Vivorx Pharmaceuticals, Inc.|Dry powder inhaler|

---

AUPN976496A0|1996-05-10|1996-05-30|Glaxo Wellcome Australia Ltd|Unit dose dispensing device|

---

US6595202B2|1996-05-13|2003-07-22|Universidad De Sevilla|Device and method for creating aerosols for drug delivery|

---

DE19622124A1|1996-06-01|1997-12-04|Alfred Von Schuckmann|Device for applying liquids|

---

US6158676A|1996-06-21|2000-12-12|Hughes Technology Group, L.L.C.|Micro-atomizing device|

---

US5906198A|1996-07-16|1999-05-25|Flickinger; William J.|Nasal nebulizer|

---

DE19704849B4|1997-02-08|2011-02-17|Ing. Erich Pfeiffer Gmbh|Discharge device for media|

---

US5824684A|1997-02-21|1998-10-20|Synapse Pharmaceuticals International, Inc.|Method for treating drug and alcohol addiction|

---

IS4516A|1997-07-01|1999-01-02|Gizurarson Sveinbjörn|New pharmaceutical form|

---

US7799337B2|1997-07-21|2010-09-21|Levin Bruce H|Method for directed intranasal administration of a composition|

---

US6200293B1|1997-08-27|2001-03-13|Science Incorporated|Fluid delivery device with temperature controlled energy source|

---

GB9719775D0|1997-09-18|1997-11-19|Glaxo Group Ltd|Device|

---

US6703374B1|1997-10-30|2004-03-09|The United States Of America As Represented By The Department Of Health And Human Services|Nucleosides for imaging and treatment applications|

---

US5954696A|1997-12-15|1999-09-21|B. Braun Medical, Inc.|Pressure infusion pump|

---

US6113078A|1998-03-18|2000-09-05|Lytesyde, Llc|Fluid processing method|

---

GB9805938D0|1998-03-19|1998-05-13|Glaxo Group Ltd|Valve for aerosol container|

---

US6062213A|1998-06-16|2000-05-16|Fuisz Technologies Ltd.|Single unit dose inhalation therapy device|

---

CA2338753C|1998-07-24|2006-11-21|Jago Research Ag|Medicinal aerosol formulations|

---

FR2782024B1|1998-08-04|2000-10-13|Valois Sa|DISPENSING HEAD AND DEVICE FOR DISPENSING A FLUID PRODUCT COMPRISING SUCH A HEAD|

---

GB2345010B|1998-12-17|2002-12-31|Electrosols Ltd|A delivery device|

---

US6294153B1|1998-12-21|2001-09-25|Generex Pharmaceuticals, Inc.|Aerosol pharmaceutical formulation for pulmonary and nasal delivery|

---

US6491940B1|1999-01-27|2002-12-10|Bruce H. Levin|Apparatus for administering composition for inhibiting cerebral neurovascular disorders and muscular headaches|

---

CA2364009C|1999-03-03|2007-02-27|Per Gisle Djupesland|Nasal delivery device|

---

CA2367409A1|1999-03-12|2000-09-21|Glaxo Group Limited|Metering valve|

---

AU3751700A|1999-03-17|2000-10-04|Emsar, Inc.|Apparatus and method for dispensing a medicinal spray|

---

EE200100500A|1999-03-26|2003-02-17|Pozen Inc.|High Power Dihydroergotamine Compositions|

---

DE19944209A1|1999-09-15|2001-03-22|Pfeiffer Erich Gmbh & Co Kg|Dispenser for possibly atomizing the discharge of a medium, in particular a liquid, from a container|

---

US6211230B1|1999-09-27|2001-04-03|The United States Of America As Represented By The Secretary Of The Army|Method of reducing brain damage resulting from seizures|

---

DE60007593T2|1999-10-14|2004-11-11|Becton, Dickinson And Co.|Nasal delivery device with atomizing nozzle|

---

US6382204B1|1999-10-14|2002-05-07|Becton Dickinson And Company|Drug delivery system including holder and drug container|

---

US6367471B1|1999-11-01|2002-04-09|Sheffield Pharmaceuticals, Inc.|Internal vortex mechanism for inhaler device|

---

US6248363B1|1999-11-23|2001-06-19|Lipocine, Inc.|Solid carriers for improved delivery of active ingredients in pharmaceutical compositions|

---

JP2003516360A|1999-12-09|2003-05-13|カイロンコーポレイション|Method of administering cytokine to central nervous system and lymphatic system|

---

US6810872B1|1999-12-10|2004-11-02|Unisia Jecs Corporation|Inhalant medicator|

---

US6302101B1|1999-12-14|2001-10-16|Daniel Py|System and method for application of medicament into the nasal passage|

---

WO2001052937A1|2000-01-24|2001-07-26|Medtronic Minimed, Inc.|Mixed buffer system for stabilizing polypeptide formulations|

---

US6540983B1|2000-01-25|2003-04-01|Aeropharm Technology Incorporated|Medical aerosol formulation|

---

US6585957B1|2000-01-25|2003-07-01|Aeropharm Technology Incorporated|Medicinal aerosol formulation|

---

US6644305B2|2000-04-14|2003-11-11|Trudell Medical International|Nasal inhaler|

---

JP4684461B2|2000-04-28|2011-05-18|パナソニック株式会社|Method for manufacturing magnetic element|

---

GB0015309D0|2000-06-21|2000-08-16|Djupesland Per G|Apparatus|

---

IT1317998B1|2000-06-26|2003-07-21|Medical Internat Licensing N V|DISPENSING VALVE FOR NASAL SPRAY.|

---

IT1318646B1|2000-07-26|2003-08-27|Medical Internat Licensing N V|NOZZLE PR ADMINISTRATIONS AND NASAL WASHES.|

---

WO2002009707A1|2000-07-31|2002-02-07|Nycomed Danmark A/S|Fentanyl composition for nasal administration|

---

CA2359813C|2000-10-24|2008-04-22|Richard L. Jones|Nicotine mucosal spray|

---

US6644309B2|2001-01-12|2003-11-11|Becton, Dickinson And Company|Medicament respiratory delivery device and method|

---

US6722364B2|2001-01-12|2004-04-20|Becton, Dickinson And Company|Medicament inhalation delivery devices and methods for using the same|

---

WO2002056948A1|2001-01-17|2002-07-25|Vectura Limited|An inhaler device|

---

ZA200306564B|2001-02-26|2004-10-15|Optinose As|Nasal devices.|

---

EP1370318B1|2001-03-15|2005-07-20|The Government of the United States of America, as represented by the Secretary, Department of Health &amp; Human Services|Systems and methods for aerosol delivery of agents|

---

GB0109001D0|2001-04-10|2001-05-30|Glaxo Group Ltd|Dispenser|

---

GB0109002D0|2001-04-10|2001-05-30|Glaxo Group Ltd|Dispenser|

---

WO2002092154A1|2001-04-26|2002-11-21|New England Pharmaceuticals, Inc.|Metered dose delivery device for liquid and powder agents|

---

EP1392262A1|2001-05-24|2004-03-03|Alexza Molecular Delivery Corporation|Delivery of drug esters through an inhalation route|

---

GB0114272D0|2001-06-12|2001-08-01|Optinose As|Nasal delivery device|

---

EP1279404A1|2001-07-26|2003-01-29|Istituto Superiore di Sanità|Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases|

---

GB0121568D0|2001-09-06|2001-10-24|Optinose As|Nasal delivery device|

---

WO2003026559A2|2001-09-28|2003-04-03|Kurve Technology, Inc|Nasal nebulizer|

---

GB2380410B|2001-10-05|2003-11-19|Alchemy Healthcare Ltd|Apparatus for the nasal or oral delivery of a medicament|

---

US7229593B1|2001-10-25|2007-06-12|Sandia Corporation|Portable vapor diffusion coefficient meter|

---

US7021561B2|2001-12-18|2006-04-04|Becton, Dickinson And Company|Spray device and method|

---

GB2384190A|2002-01-22|2003-07-23|Bespak Plc|Dispensing device for a powdered product|

---

EP1670500A2|2003-09-17|2006-06-21|Chiasma, Ltd.|Compositions capable of facilitating penetration across a biological barrier|

---

GB0204829D0|2002-03-01|2002-04-17|Glaxo Group Ltd|A fluid dispensing device|

---

US7666876B2|2002-03-19|2010-02-23|Vernalis Limited|Buprenorphine formulations for intranasal delivery|

---

GB0207422D0|2002-03-28|2002-05-08|Optinose As|Nasal devices|

---

GB0209494D0|2002-04-25|2002-06-05|Optinose As|Nasal devices|

---

US7655619B2|2002-05-06|2010-02-02|Thomas Jefferson University|Insulin-associated peptides with effects on cerebral health|

---

US8122881B2|2002-05-09|2012-02-28|Kurve Technology, Inc.|Particle dispersion device for nasal delivery|

---

US7220457B2|2002-06-06|2007-05-22|Anderson Steven R|Air atomizing assembly and method and system of applying an air atomized material|

---

GB0215270D0|2002-07-02|2002-08-14|Optinose As|Nasal devices|

---

GB0215904D0|2002-07-09|2002-08-21|Team Holdings Uk Ltd|Drug delivery system and method|

---

GB0217198D0|2002-07-25|2002-09-04|Glaxo Group Ltd|Medicament dispenser|

---

DE10241640A1|2002-09-05|2004-03-18|Boehringer Ingelheim Pharma Gmbh & Co. Kg|Needle-less syringe or inhaler for administering aqueous or aqueous-alcohol formulations of drugs comprises casing containing spring-loaded piston, into which cartridge with integral diffuser head can be introduced|

---

US6966990B2|2002-10-11|2005-11-22|Ferro Corporation|Composite particles and method for preparing|

---

US20060104968A1|2003-03-05|2006-05-18|Halozyme, Inc.|Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases|

---

GB0309354D0|2003-04-24|2003-06-04|Glaxo Group Ltd|Nozzle for a nasal inhaler|

---

DE10321902A1|2003-05-06|2004-12-09|Ing. Erich Pfeiffer Gmbh|Discharge device for at least one medium|

---

GB0313604D0|2003-06-12|2003-07-16|Britannia Pharmaceuticals Ltd|Delivery device for powdered medicament|

---

GB0319119D0|2003-08-14|2003-09-17|Optinose As|Delivery devices|

---

GB0320171D0|2003-08-28|2003-10-01|Optinose As|Delivery devices|

---

WO2005023335A2|2003-09-05|2005-03-17|Kurve Technology, Inc.|Integrated nebulizer and particle dispersing chamber for delivery of medicament|

---

GB0322284D0|2003-09-23|2003-10-22|Glaxo Group Ltd|Medicament dispenser|

---

WO2006004646A1|2004-06-28|2006-01-12|Nektar Therapeutics|Aerosol formulation comprising nicotine salt|

---

KR20070073865A|2004-10-06|2007-07-10|베링거 인겔하임 인터내셔날 게엠베하|Dispensing device, storage device and method for dispensing powder|

---

US7832394B2|2004-12-22|2010-11-16|Schechter Alan M|Apparatus for dispensing pressurized contents|

---

GB0503738D0|2005-02-23|2005-03-30|Optinose As|Powder delivery devices|

---

US20060198940A1|2005-03-04|2006-09-07|Mcmorrow David|Method of producing particles utilizing a vibrating mesh nebulizer for coating a medical appliance, a system for producing particles, and a medical appliance|

---

CN101175479A|2005-03-16|2008-05-07|霍尼韦尔国际公司|Medicament delivery formulations, devices and methods|

---

DE602006008625D1|2005-04-01|2009-10-01|Intezyne Technologies Inc|POLYMERMICELLES FOR DRUG DELIVERY|

---

US20060260606A1|2005-05-18|2006-11-23|Coifman Robert E|Inhalable formulations of amphotericin B and methods and devices for delivery thereof|

---

GB0515592D0|2005-07-28|2005-09-07|Glaxo Group Ltd|Nozzle for a nasal inhaler|

---

WO2007035913A2|2005-09-21|2007-03-29|Kurve Technology, Inc.|Medicament delivery control, monitoring, and reporting system and method|

---

JP4765526B2|2005-10-04|2011-09-07|オムロンヘルスケア株式会社|Inhaler and mouthpiece for inhaler|

---

WO2007058902A1|2005-11-11|2007-05-24|Aurogen Inc.|Method for treating disease or disorder of adult central nervous system associated with tissue shrinkage or atrophy by administration of insulin|

---

EP1960022A1|2005-11-29|2008-08-27|Alza Corporation|Nasal delivery device for the delivery of a substance to the olfactory region|

---

EP1792660A1|2005-12-02|2007-06-06|Boehringer Ingelheim Pharma GmbH & Co. KG|Dispensing device|

---

DE102006001113B3|2006-01-09|2007-06-28|Pari GmbH Spezialisten für effektive Inhalation|Aerosol therapy device comprises an atomizer, an aerosol generator, a nosepiece for delivering aerosol to one nostril, a device for creating flow resistance in the other nostril, and a connector that imparts pressure fluctuations|

---

US20070202051A1|2006-02-10|2007-08-30|Pari Gmbh|Aerosols for sinunasal drug delivery|

---

GB2434990B|2006-02-14|2010-12-01|Optinose As|Delivery device and method|

---

GB0604444D0|2006-03-06|2006-04-12|Optinose As|Nasal devices|

---

GB0605799D0|2006-03-23|2006-05-03|Optinose As|Nasal delivery devices|

---

US7841338B2|2006-04-13|2010-11-30|Boehringer Ingelheim International Gmbh|Dispensing device|

---

GB2440316A|2006-07-25|2008-01-30|Optinose As|Nasal inhaler with scrubber|

---

CA2698137A1|2006-08-30|2008-03-06|Kurve Technology, Inc.|Aerosol generating and delivery device|

---

US20080173301A1|2006-09-06|2008-07-24|Daniel Deaton|Variable dose aerosol drug canister|

---

US20080066739A1|2006-09-20|2008-03-20|Lemahieu Edward|Methods and systems of delivering medication via inhalation|

---

US8042536B1|2006-10-18|2011-10-25|Care 2 Medical|Nebulizer apparatus|

---

EP1915986A1|2006-10-23|2008-04-30|BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH|Lipid growth factor formulations|

---

FR2908753B1|2006-11-16|2011-11-11|Becton Dickinson France|DEVICE FOR AUTOMATICALLY DELIVERING SUCCESSIVE PRODUCT DOSES|

---

WO2008067254A2|2006-11-27|2008-06-05|Abbott Respiratory Llc|Nasal drug delivery device and method|

---

GB0623732D0|2006-11-28|2007-01-10|Optinose As|Powder delivery devices|

---

GB0623728D0|2006-11-28|2007-01-10|Optinose As|Delivery devices|

---

US20100143503A1|2006-12-22|2010-06-10|Ikaria, Inc.|Combinations of nitric oxide and sulfide and methods of use and manufacture thereof|

---

EP2111553B1|2007-01-24|2018-09-19|Carnegie Mellon University|Optical biosensors|

---

WO2008097664A1|2007-02-11|2008-08-14|Map Pharmaceuticals, Inc.|Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile|

---

US7845359B2|2007-03-22|2010-12-07|Pierre Denain|Artificial smoke cigarette|

---

GB2448193A|2007-04-05|2008-10-08|Optinose As|Nasal delivery device|

---

US8530463B2|2007-05-07|2013-09-10|Hale Biopharma Ventures Llc|Multimodal particulate formulations|

---

JP2011504163A|2007-06-08|2011-02-03|ヘルスパートナーズリサーチファウンデーション|Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system|

---

US20090151722A1|2007-07-06|2009-06-18|Vectura Delivery Devices Limited|Inhaler|

---

EP2030644A1|2007-08-31|2009-03-04|PARI Pharma GmbH|Aerosols for sinunasal drug delivery|

---

GB0719299D0|2007-10-03|2007-11-14|Optinose As|Nasal delivery devices|

---

WO2009049215A1|2007-10-10|2009-04-16|Wake Forest University Health Sciences|Methods to reduce the effects of sleep deprivation|

---

EP3272379A1|2008-02-07|2018-01-24|The University of Washington|Circumferential aerosol device|

---

EP2242526A4|2008-02-15|2014-06-18|Timothy Sean Immel|Aerosol therapy device with high frequency delivery|

---

US8517026B2|2008-02-25|2013-08-27|Adva Beck Amon|Nasal inserts|

---

GB0803551D0|2008-02-26|2008-04-02|Microsharp Corp Ltd|Prismatic lenses|

---

CN102065694A|2008-04-15|2011-05-18|萨可德公司|Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders|

---

NO329804B1|2009-02-09|2010-12-20|Fmc Kongsberg Subsea As|Link for use in a riser, riser with such a link and method for increasing the operating window of a riser|

---

WO2010131486A1|2009-05-15|2010-11-18|Shin Nippon Biomedical Laboratories, Ltd.|Intranasal pharmaceutical compositions with improved pharmacokinetics|

---

US8839790B2|2009-07-29|2014-09-23|Adva Beck Arnon|Nasal inserts|

---

GB2472327B|2009-07-31|2013-03-13|Shin Nippon Biomedical Lab Ltd|Intranasal granisetron and nasal applicator|

---

US8408427B2|2009-09-07|2013-04-02|Mk International Pty Ltd|Single dose nasal spray pump|

---

US8162921B2|2009-12-08|2012-04-24|Medinvent, Llc|Method and device for nasal irrigation and drug delivery|

---

US8925544B2|2009-12-08|2015-01-06|Medinvent, Llc|Portable nebulizer device|

---

EP2605816B1|2010-08-20|2019-01-23|University Of Washington|Circumferential aerosol device for delivering drugs to olfactory epithelium and brain|

---

CA2820554A1|2010-11-29|2012-06-07|Sanofi-Aventis Deutschland Gmbh|Medicated module for an inhaler|

---

BR112013022249A2|2011-03-03|2020-04-28|Impel Neuropharma Inc|nasal drug delivery device|

---

EP3851142A1|2011-05-09|2021-07-21|Impel NeuroPharma Inc.|Nozzles for nasal drug delivery|

---

US8987199B2|2011-06-15|2015-03-24|Nerve Access, Inc.|Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders|

---

DE102012201178B3|2012-01-27|2013-02-14|Aptar Radolfzell Gmbh|Nozzle unit and dispenser with such|

---

US20150216993A1|2012-04-18|2015-08-06|The Regents Of The University Of Michigan|Multifunctional small molecules|

---

WO2014031964A1|2012-08-24|2014-02-27|Vr1, Inc.|Composition for the treatment of migraine headaches|

---

DE102013100473A1|2013-01-17|2014-07-17|Seho Systemtechnik Gmbh|Method and device for cleaning a soldering nozzle|

---

US10537692B2|2013-04-28|2020-01-21|Impel Neuropharma, Inc.|Medical unit dose container|

---

WO2015044782A2|2013-09-24|2015-04-02|Shin Nippon Biomedical Laboratories, Ltd.|Intranasal dhe for the treatment of headache|

---

US9603905B2|2014-03-13|2017-03-28|The Research Foundation For Mental Hygiene, Inc|Intranasal insulin administration for the minimization of anesthesia-induced memory loss|BR112013022249A2|2011-03-03|2020-04-28|Impel Neuropharma Inc|nasal drug delivery device|

---

EP3851142A1|2011-05-09|2021-07-21|Impel NeuroPharma Inc.|Nozzles for nasal drug delivery|

---

US10537692B2|2013-04-28|2020-01-21|Impel Neuropharma, Inc.|Medical unit dose container|

---

GB201401659D0|2014-01-31|2014-03-19|3M Innovative Properties Co|Actuator for an inhaler|

---

US10751489B2|2014-05-19|2020-08-25|Inhaletech Llc|Device and method for administering medicaments to the brain|

---

WO2017011326A1|2015-07-10|2017-01-19|Sanjay Gupta|Nasal foam via cribriform plate for medication delivery to the brain and/or body and for nasal moisturization and hygiene|

---

KR20180052662A|2015-09-10|2018-05-18|임펠 뉴로파마 인코포레이티드|In-line nose delivery device|

---

EP3162404B1|2015-10-29|2018-02-14|W & H Dentalwerk Bürmoos GmbH|Dental device for delivering a powdery medium|

---

EP3377089B1|2015-11-18|2020-04-08|Herantis Pharma Plc|Compositions comprising cdnf for use in the intranasal treatment of central nervous system diseases|

---

US10940274B2|2015-12-01|2021-03-09|Cipla Limited|Nasal spray assembly|

---

FR3046553B1|2016-01-07|2018-02-16|Aptar France Sas|NASAL DISTRIBUTION SET OF FLUID PRODUCT.|

---

KR101978554B1|2016-05-17|2019-05-16|한양대학교 산학협력단|Drug Delivery Device for nasal cavity to brain|

---

WO2017205610A1|2016-05-25|2017-11-30|University Of Florida Research Foundation, Inc.|Use of angiotensin ii receptor agonists in the treatment and prevention of stroke|

---

GB201619637D0|2016-11-21|2017-01-04|Pekna Marcela And Pekny Milos And Stokowska Anna|C3a receptor agonists|

---

EP3634528A4|2017-06-07|2021-03-10|Shifamed Holdings, LLC|Intravascular fluid movement devices, systems, and methods of use|

---

KR102168749B1|2017-11-17|2020-10-22|한양대학교 산학협력단|Brain drug delivery device through nasal cavity and brain drug delivery method through nasal cavity|

---

US20190151576A1|2017-11-21|2019-05-23|Impel Neuropharma, Inc.|Intranasal device with inlet interface|

---

US10391269B2|2017-11-29|2019-08-27|Meshil A. M. O. H. Al-Jarba|Nasal sprayer with multiple applicators|

---

CN111936140A|2018-01-05|2020-11-13|英倍尔药业股份有限公司|Intranasal delivery of dihydroergotamine through precision nasal device|

---

AU2019205327A1|2018-01-05|2020-07-30|Impel Neuropharma, Inc.|Intranasal delivery of levodopa powder by precision olfactory device|

---

JP2021511894A|2018-02-01|2021-05-13|シファメド・ホールディングス・エルエルシー|Intravascular blood pump and method of use and manufacture|

---

AU2019418744A1|2019-01-03|2021-07-22|Impel Neuropharma, Inc.|Nasal drug delivery device|

---

CA3146050A1|2019-07-04|2021-01-07|Sw Holdings, Inc.|Metered dosing compositions and methods of use of psychedelic compounds|

---

WO2021185343A1|2020-03-20|2021-09-23|江苏恒瑞医药股份有限公司|Glyburide liposome composition and preparation method therefor|

---

WO2021191904A1|2020-03-26|2021-09-30|Tree Of Life Pharma Ltd.|Methods for preventing and treating viral infection|

---

RU2745231C9|2020-06-08|2021-04-27|Акционерное общество "Столетика"|Spray inhaler with preparation and storage functions|

---

GB202011729D0|2020-07-29|2020-09-09|Kindeva Drug Delivery Lp|Device for delivery of a compound to a region of the nasal cavity|

法律状态:
2020-05-12| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2020-06-23| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |

---

2020-09-29| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|

---

2020-11-10| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2021-05-04| B07A| Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]|

---

2021-10-13| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|

---

2021-10-19| B350| Update of information on the portal [chapter 15.35 patent gazette]|

优先权:

---

申请号 | 申请日 | 专利标题

---

US201161449008P| true| 2011-03-03|2011-03-03|

---

US201161451935P| true| 2011-03-11|2011-03-11|

---

US201161484025P| true| 2011-05-09|2011-05-09|

---

US201161498974P| true| 2011-06-20|2011-06-20|

---

PCT/US2012/027754|WO2012119153A2|2011-03-03|2012-03-05|Nasal drug delivery device|

---